

Northumbria Research Link

Citation: Winnard, Andrew, Scott, J., Waters, Nathan, Vance, M. and Caplan, Nick (2019) Effect of time on human muscle outcomes during simulated microgravity exposure without countermeasures - systematic review. *Frontiers in Physiology*, 10. p. 1046. ISSN 1664-042X

Published by: Frontiers

URL: <https://doi.org/10.3389/fphys.2019.01046>
<<https://doi.org/10.3389/fphys.2019.01046>>

This version was downloaded from Northumbria Research Link:
<http://nrl.northumbria.ac.uk/id/eprint/39830/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)

1 Effect of time on human muscle outcomes during simulated microgravity
2 exposure without countermeasures – systematic review.
3

4 Winnard, A.*¹, Scott J², Waters, N.¹, Vance, M.¹, & Caplan, N.¹

5
6 ¹Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United
7 Kingdom

8 ² Space Medicine Office, European Astronaut Centre, Cologne, Germany
9

10 Corresponding author:

11 Dr Andrew Winnard

12 Faculty of Health and Life Sciences

13 Northumbria University

14 Northumberland Building

15 Newcastle upon Tyne

16 NE1 8ST

17 Tel: +44 (0)191 243 3217

18 Email: A.Winnard@northumbria.ac.uk
19
20

21 Keywords:

22 Muscle

23 Microgravity

24 Spaceflight

25 Deconditioning

26 Astronaut
27

28 Words:

29 Abstract: 360

30 Main text: 8063

31 Figures: 13

32 Tables: 2
33

34 Abstract

35 **Background**

36 Space Agencies are planning human missions beyond Low Earth Orbit. Consideration of how
37 physiological system adaptation with microgravity (μG) will be managed during these mission
38 scenarios is required. Exercise countermeasures (CM) could be used more sparingly to
39 decrease limited resource costs, including periods of no exercise. This study provides a
40 complete overview of the current evidence, making recommendations on the length of time
41 humans exposed to simulated μG might safely perform no exercise considering muscles only.

42
43 **Methods**

44 Electronic databases were searched for astronaut or space simulation bed rest studies, as the
45 most valid terrestrial simulation, from start of records to July 2017. Studies were assessed with
46 the Quality in Prognostic Studies and bed rest analogue studies assessed for transferability to
47 astronauts using the Aerospace Medicine Systematic Review Group Tool for Assessing Bed
48 Rest Methods. Effect sizes, based on no CM groups, were used to assess muscle outcomes
49 over time. Outcomes included were contractile work capacity, muscle cross sectional area,
50 muscle activity, muscle thickness, muscle volume, maximal voluntary contraction force during
51 one repetition maximum, peak power, performance based outcomes, power and
52 torque/strength.

53
54 **Results**

55 75 bed rest μG simulation studies were included, many with high risk of confounding factors
56 and participation bias. Most muscle outcomes deteriorated over time with no countermeasures.
57 Moderate effects were apparent by 7-15 days and large by 28-56 days. Moderate effects (>0.6)
58 became apparent in the following order, power and MVC during one repetition maximum (7
59 days), followed by volume, cross sectional area, torques and strengths, contractile work
60 capacity, thickness and endurance (14 days), then muscle activity (15 days). Large effects
61 (>1.2) became apparent in the following order, volume, cross sectional area (28 days) torques
62 and strengths, thickness (35 days) and peak power (56 days).

63
64 **Conclusions**

65 Moderate effects on a range of muscle parameters may occur within 7-14 days of unloading,
66 with large effects within 35 days. Combined with muscle performance requirements for
67 mission tasks, these data, may support the design of CM programmes to maximise efficiency
68 without compromising crew safety and mission success when incorporated with data from
69 additional physiological systems that also need consideration.

70

71 1. Introduction

72 1.1. Rationale

73 Space Agencies are planning to transition from International Space Station (ISS) missions to
74 Lunar missions including a crewed base from which to test and develop hardware and
75 procedures required for the longer term goal of human Mars missions (Foing 2016). It is well
76 documented that exposure to microgravity (μG) during spaceflight causes adaptation in
77 response to gravitational unloading, especially in the musculoskeletal, cardiovascular and
78 neuro-vestibular systems (Buckey 2006, Baker 2008). The risks to mission success due to
79 potential injury or reduced function due to periods of unmanaged adaptation before arriving
80 at a remote location such as Moon or Mars, where medical teams may not be present on
81 landing, need to be addressed (Gernand 2004). Bed rest is often used as a controlled Earth-
82 based environment for simulating the effects of spaceflight on humans to enable more cost-
83 effective, higher quality and safer research into effects and medical management of
84 adaptation (Pavy-Le Traon, Heer et al. 2007). While bed rest fails to remove a Gx (chest-to-
85 back) loading vector, such studies are considered the most valid simulation method for many
86 physiological systems (Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007), except
87 for weight bearing, tissue fluid redistributions and skin surface areas of compression
88 (Hargens and Vico 2016), and when conducted rigorously are likely to generate results
89 transferable to astronauts (Higgins and Green 2011, Winnard and Nasser 2017).

90 Based on bed rest research and previous spaceflight experience, the ISS provides astronauts
91 with 2.5 hours per day for exercise (including setup, stowage and hygiene) using a treadmill,
92 cycle ergometer and resistance exercise device designed and adapted for μG (Trappe, Costill
93 et al. 2009, Loehr, Lee et al. 2011). Several years of refining ISS exercise countermeasures
94 (CM) has led to astronauts completing 6-month missions with, on average, little to no change
95 in bone mass or cardiovascular capacity, although the efficacy seems to vary widely between
96 individuals (Moore., Downs et al. 2014, English, Lee et al. 2015, Sibonga, Spector et al.
97 2015), while muscle adaptation appears to have become progressively smaller as exercise
98 devices and prescriptions have improved (Smith, Heer et al. 2012, Moore., Downs et al.
99 2014, Ploutz-Snyder, Ryder et al. 2015). However, the exercise devices currently aboard ISS
100 will almost certainly be too large and too numerous for, and the exercise prescriptions place
101 too great a demand on the consumables and environmental management systems available
102 on, the vehicles and habitats currently planned for future exploration missions. For this
103 reason, space agencies have started designing smaller, low energy and low vibration exercise
104 devices (Brusco 2016). However, decisions will need to be made regarding choice and/or
105 development of an effective exercise CM programme to manage physiological adaptation that
106 will occur during exploration missions. Considerations may include reducing the frequency
107 of exercise as currently performed on ISS and potentially having longer periods of not
108 performing any exercise. The duration of any such no exercise periods needs to be evidence
109 based to balance any increase physiological risks to crew against gains in spacecraft and
110 consumables impact.

111 1.2. Objectives

112 The objectives of this review were to provide a complete summary of and synthesise the
113 current space-related physiological evidence base and to inform decision making processes
114 around muscle performance requirements, regarding operational CM, for exploration human
115 space missions. Where data is lacking for any outcomes this will be highlighted as a gap or
116 limited area of the current evidence base and used to provide a gap analysis commentary
117 useful for future research priority setting. The aim is to aid space agencies in designing CM
118 programmes, provide a complete summary of what muscle groups and outcomes have been
119 assessed in the current evidence and highlight areas of minimal data or research gaps to guide
120 future relevant research in this area. The NASA Risk Table for the Human Research Project
121 highlights potential risks relating to spaceflight and shows the large scope of potential
122 physiological systems that require reviewing to cover all elements of crew health and
123 performance (NASA 2019). As the scope is too large for a single review, it is suggested that
124 the various systems be reviewed individually. Once a series of reviews has been complete a
125 position statement summarising across each system can provide a holistic overview.
126 Therefore, this specific review investigated the rate at which muscle parameters change during
127 simulated μG exposure, when no countermeasures are taken, to inform operational decisions
128 regarding the possibility of using exercise CM programmes more sparingly for exploration
129 missions, including the implementation of exercise ‘holidays; (i.e. a period of time within the
130 mission when no exercise CM are employed). Conclusions of this review alone must be
131 treated in a muscle context and need considering alongside other relevant health and
132 performance components.

133 1.3. Research question

134 At what time point do people exposed to simulated μG while not performing CM reach a
135 moderate or large effect on muscle health outcomes?

136 2. Methods

137 2.1. Study design

138 The Cochrane Collaboration Guidebook (Higgins and Green 2011) and preferred reporting
139 items for systematic reviews and meta-analyses (PRISMA) were adhered to (Moher, Liberati
140 et al. 2009). No external funding or research grants were received for this work.

141 2.1.1. Participants

142 The following inclusion criteria were employed. The target population was astronauts,
143 however, as astronauts have taken part in space agency recommended exercise programmes
144 to date, there was no inactive data available from this population. Therefore, healthy
145 terrestrial adults, with no gender restrictions, taking part in μG analogue bed rest studies,
146 were included. Bed rest studies were the only terrestrial model included as they are
147 considered the most valid ground based model for simulating human spaceflight for periods
148 beyond a few minutes (Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007).
149 Therefore to maintain the greatest level of transferability to astronauts and in keeping with
150 our other systematic reviews only bed rest studies that stated they were simulating human
151 spaceflight were considered. No clinical bed rest situations such as critical care were

152 included as they would likely have confounding co-morbidities and not transfer well to
153 astronauts. All participants in the included bed rest studies were healthy at baseline,
154 however, no exclusion was made relating to baseline level of physical condition beyond
155 being healthy. Only control group data were relevant, therefore no inclusion criteria were
156 based on interventions. Control groups had to be inactive and not undergo any type of
157 intervention. Included studies had to report outcomes relating to muscles. For completeness
158 of reporting the current state of the evidence base and avoid introducing selection bias, no
159 exclusion was made based on type of outcome or amount of data. The evidence based led
160 outcomes were determined from pre-scoping and the main review searches and were grouped
161 for analysis as cross-sectional area, volume, shape, size, activity, power, performance and
162 joint torque and forces at either a regional or global level. Included studies had to be
163 randomised controlled trials (RCT), controlled clinical trials (CT), longitudinal, interrupted
164 time series or before and after studies.

165 2.2. Systematic review protocol

166 2.2.1. Search strategy, data sources, studies sections and data extraction

167 A range of relevant terms grouped by main search terms were constructed using Boolean
168 logic (astronaut*, spaceflight, space flight, space*, weightless*, microgravity, micro gravity,
169 bed-rest, bedrest, bed rest, dry immersion, muscle*, strength*) to search the following
170 databases up to July 2017: Pubmed, CINAHL, Web of Science, NASA Technical Reports
171 Server and The Cochrane Collaboration Library. No restrictions on type of bed rest or
172 publication dates were applied, and due to the inability to use 'Boolean logic' on the NASA
173 Technical Reports Server, the strategy was adapted to keyword searches. The full search
174 strategy is available in Table 1.

175 *** insert table 1 here ***

176 Initial screening was performed using abstracts and titles by two authors (MV and AW),
177 blinded to each other's decisions, using Rayyan (<https://rayyan.qcri.org/>) (Ouzzani,
178 Hammady et al. 2016). Rayyan also automatically detects duplicate studies and data and all
179 flagged potential duplication was assessed by agreement of three blinded authors. Where
180 there was any disagreement whether the study met the inclusion criteria from initial screening
181 the full text was obtained. A third author (NC) was used to resolve disagreements of
182 included/excluded studies. An adapted version of the Aerospace Medicine Systematic
183 Review Group (AMSRG) 'Data extraction form', version 2, July 2017, (AMSRG 2018) was
184 used by two authors (MV and NW) to extract data from each paper, and disagreements were
185 discussed by three authors (AW, NW and MV) to reach consensus.

186 2.3. Data analysis

187 2.3.1. Quality assessment

188 The Quality in Prognostic Studies (QUIPS) tool was used to assess risk of bias of all
189 the included studies, with 'H', 'M' and 'L' showing high, moderate and low risk respectively,
190 using pre-defined published definitions for each level (Hayden, van der Windt et al. 2013).
191 Risk of bias results were used to comment on the current quality and completeness of the

192 evidence base and do not change how studies were treated during analysis. As per published
193 recommendations, only studies that were rated low risk of bias in all QUIPS domains were
194 deemed as low risk overall (Hayden, van der Windt et al. 2013). The AMSRG ‘Tool for
195 Assessing Bed Rest Methods’ (Winnard and Nasser 2017a, Winnard and Nasser 2017) was
196 used to assess the bed rest methodological quality, and transferability to astronaut
197 populations, of all included studies, with ‘y’ indicating the point was met, ‘n’ not met and ‘?’
198 unclear. This is a relatively new tool, yet to be validated, that has been used in several other
199 reviews (Richter, Braustein et al. 2017, Winnard, Nasser et al. 2017) and the development of
200 the tool is explained in Winnard et al (2017).

201 2.3.2. Main analysis

202 Effect sizes (Hedges’ g) were calculated between pre and post bed rest values for each
203 outcome individually without an overall pooled effect. Hedges’ g was used to bias correct for
204 the typically small sample sizes, as only control group data from μ G simulation studies were
205 eventually included. The reported data set that was as close to immediate pre and the end of
206 bed rest was used for the analysis. No exclusion or analysis variation was made based on the
207 individual study analysis methods. The pooled standard deviation for Hedges’ g was
208 calculated using the root mean square of the pre and post group standard deviations. This
209 version does not specifically include the sample size (n), preventing any complications that
210 could arise from inflating n when both group means are from the same sample. Results were
211 first sub-grouped by outcome measure type and then by muscle group before being listed in
212 order of ascending days spent in simulated μ G. Individual effects sizes were calculated and
213 plotted in figures for each outcome at every time point where data were available. To enable
214 a brief overview of the large data set to also be provided, an unweighted mean effect at each
215 common time point within each muscle group was used to provide a summary result. This
216 was only done when more than one study assessed the same outcome at the same time point.
217 These statistics were chosen due to data being from the same sample rather than a separate
218 intervention and control group, thus making a traditional weighted effects meta-analysis
219 pooling inappropriate. Traditional meta-analysis assumes two different sets of individuals in
220 each group (Higgins and Green 2011) meaning a violation of underlying assumptions would
221 have occurred if applied to this review. The summary unweighted mean, while being a less
222 robust statistic, enabled an overarching overview to be reported in addition to each individual
223 effect size, and overlaid on the figures, without violating statistical assumptions. 95%
224 confidence intervals were calculated for individual and unweighted group means. Readers
225 should note that due to varying effect sizes across the various muscles and groupings, the
226 effect size axis scale varies accordingly throughout the figures.

227 The point at which effects consistently reached a magnitude of 0.6 (moderate) or 1.2 (large)
228 was highlighted as a time point when a worthwhile mechanistic change had occurred
229 (Hopkins, Marshall et al. 2009). Plots of all individual effects and 95% confidence interval
230 tails, in order of ascending days in simulated μ G, were overlaid with the mean effect and
231 polynomial trend line of the mean effects. A polynomial trend allowed for the trend line to
232 curve in case of progressively worsening, or plateauing patterns. In cases where data were
233 lacking and varied (spanning more than one effect size cut off between data points), the trend

234 line was highlighted as likely unreliable in the results section, meaning more data should be
235 collected before a reliable trend can be established. The limited data sets are however still
236 included for completeness of reporting the current state of the evidence base and highlight
237 both minimal data areas and research gaps. The mean effect summary and trend line were
238 only used to visually highlight the time point at which the mean effects passed the 0.6 and 1.2
239 magnitude point. A funnel plot of all the mean effects plotted against study size was used to
240 show potential publication bias.

241 2.3.3. Sub group analysis

242 Ten sub groups were created based on the measurement methods units used for each for
243 analysis as follows (with original units measured in): **(1)** contractile work capacity (J), **(2)**
244 cross sectional area (mm², cm²), **(3)** muscle activity (μV, mV, normalised), **(4)** muscle
245 thickness (mm, cm), **(5)** muscle volume (cm³), **(6)** maximal voluntary contraction force
246 during one repetition maximum (kg, N, Nm) **(7)**, peak power (W), **(8)** performance based
247 outcomes (including endurance time, jump power, force, velocity height and acceleration, sit
248 to stand time, centre of mass variation and sprint time)(s, mm, cm, m, W/kg), **(9)** power
249 (rad·s⁻¹, m.s⁻¹) and **(10)** torques and strength (Nm, ft-lb). Within each subgroup data were
250 further sub-grouped for analysis by major muscle groups. For completeness of reporting, any
251 measures that did not fit within major muscle groupings were grouped for analysis and
252 reported as either “other lower limb”, “other trunk” or “other upper limb” outcomes, to
253 enable every outcome measure extracted from included studies to be reported in the results.
254 The outcomes included in the “other” groupings are listed in the text.

255 3. Results

256 3.1. Study selection, characteristics and risk of bias

257 In total, 112 studies were included after duplicates removed, all of which were screened for
258 inclusion into the analysis. There were 37 not included in the analysis due the reasons
259 provided in the PRISMA flow diagram (Figure 1). Therefore, 75 studies (Table 2) were
260 included, producing 922 individual effect sizes across all sub groups and outcomes. All
261 studies were bed rest μG simulations as no astronaut studies to date included an inactive
262 control group exposed to μG due to space agency recommended exercise programmes. There
263 is no comparison descriptor column in table 2 as we only considered control groups who had
264 no intervention, treated as before and after simulated μG exposure comparisons. The most
265 common bed rest duration was 60 days, with shortest and longest durations being seven and
266 120 days, respectively. The most common study design was RCT. Most of the studies
267 scored four on the bed rest quality score, with the highest score being six, and the lowest
268 score was two. Only three studies were assessed to have a low risk of bias. As only
269 intervention studies’ control group data were included and no actual prognostic studies were
270 found and included, question three on the QUIPS about prognostic factors was rated as n/a
271 for all the included studies. A rating for question 3 would have been provided had any actual
272 prognostic studies been found and included. However, for this review, time in μG can be
273 considered the prognostic factor and the quality of the μG simulation was critiqued in detail
274 within the bedrest quality scores. There is some asymmetry in the funnel plot in Figure 2,

275 suggesting potential publication bias toward studies reporting decreases in muscles, however
276 there are studies, including smaller ones, that do report an increase. Forty five studies
277 specified a time period ahead of the bed rest period in which baseline measures were
278 recorded ranging from 1-21 days. Of these, 11 (Greenleaf, Van Beaumont et al. 1983,
279 Dudley, Duvoisin et al. 1989, Greenleaf, Bernauer et al. 1989, Ellis, Kirby et al. 1993,
280 Greenleaf, Lee et al. 1994, Ferrando, Stuart et al. 1995, Portero, Vanhoutte et al. 1996, Muir,
281 Judex et al. 2011, Lee, Schneider et al. 2014, English, Mettler et al. 2016, Schneider, Lee et
282 al. 2016) stated utilising a pre-bed rest ambulatory control period in their methods section.
283 However it was not clear in any of the studies what the control period involved or if there was
284 any pre-bed rest deconditioning that was measured or adjusted for. One study, (Mulder,
285 Gerrits et al. 2008) measured baseline outcomes on day 4 of bed rest and acknowledges this
286 could have led to underestimating the effect of bed rest, especially for time sensitive
287 outcomes such as those associated with muscle. Full data tables for results per muscle are
288 available in supplementary data tables as indicated in each results sub-section. The raw data
289 supporting the conclusions of this manuscript will be made available by the authors, without
290 undue reservation, to any interested parties.

291 *** insert figure 1 here***

292 ***insert table 2 here**

293 ***insert figure 2 here***

294 3.2. Synthesised findings

295 3.2.1. Muscle volume

296 All muscle volumes decreased over time. Moderate effects were becoming apparent by 14
297 days and large by 28 days. Very little data were available for Hip Flexor, Gluteal, Multifidus
298 and Erector Spinae muscles, where a moderate or greater effect was never reached for Hip
299 Flexors and Erector Spinae muscles and only a moderate effect was apparent by 27 and 90
300 days for Gluteal and Multifidus muscles, respectively. Other lower limb muscles that
301 included Gracilis, Sartorius, Piriformis, Obturators and Pectineus muscles, reached a
302 moderate effect by 14 days. Other trunk muscles that included Levator Scapulae, Longus
303 Colli, Sternocleidomastoid and Scalene muscles never reached a moderate effect. The
304 breakdown of individual volume effects per muscle is available in supplementary data Table
305 3 and associated summary plots in Figure 3.

306 ***insert figure 3 here***

307 3.2.2. Muscle cross sectional area

308 All muscle cross sectional areas decreased over time. Moderate effects were apparent by 14
309 days and large by 28 days. The same effect time points were found for other lower limb
310 muscles that included Gracilis and Sartorius muscles and total thigh and calf cross sectional
311 area. Very little data were available for Hip Flexor, Gluteal, Hamstring and Hip Adductor
312 muscles where a moderate or greater effect was never reached. Multifidus and other trunk
313 muscles, including Quadratus Lumborum and combined Multifidus and Erector Spinae cross

314 sectional area, only reached a large effect by 60 days. Upper limb muscle outcomes
315 consisted of forearm muscle cross sectional area which only reached a large effect after 89
316 days. The breakdown of individual cross sectional area effects per muscle are available in
317 supplementary Table 4 and associated summary plots in Figure 4. The polynomial trend for
318 Dorsi Flexor muscles appeared to be unreliable.

319 ***insert Figure 4 here***

320 3.2.3. Torques and strength

321 Torques and strengths decreased over time. Moderate effects became apparent by 14 days for
322 Quadriceps muscles only. Additional moderate effects became apparently by 30 days and
323 large effects by 35 days. Dorsi Flexor, Hamstring, Hip Extensor, Hip Flexor, other trunk and
324 other upper limb muscles never reached a large effect. Other trunk muscles included trunk
325 flexors and extensors tested in combination within functional movements. Upper limb
326 muscles included elbow flexor and extensor muscles and shoulder abductor and adductor
327 muscles. The breakdown of individual torques and strength effects per muscle is available in
328 supplementary Table 5 and associated summary plots in Figure 5. The polynomial trend for
329 Dorsi Flexor muscles appeared to be unreliable after 60 days.

330 ***insert Figure 5 here***

331 3.2.4. Contractile work capacity

332 Although there are very little available data for contractile work capacity it appears to
333 decrease over time. Moderate effects became apparent by 14 days in Plantar Flexor and
334 Quadriceps muscles. However, this is based on only one study for each muscle at 14 days.
335 The breakdown of individual contractile work capacity effects per muscle is available in
336 supplementary Table 6 and associated summary plots in Figure 6. Data were limited for all
337 muscles.

338 ***insert Figure 6 here***

339 3.2.5. Muscle thickness

340 Muscle thickness decreased over time. Moderate and large effects became apparent by 14
341 days. There were very little data for Plantar Flexor, Dorsi Flexor and Quadriceps muscles,
342 showing Dorsi Flexor muscles reached a moderate effect by 35 days and only Plantar Flexor
343 and Quadriceps muscles reached a large effect by 35 days. Internal Oblique muscle reached a
344 moderate effect at 14 days. Erector Spinae muscle was similar to Internal Oblique muscle,
345 but only reached a borderline moderate effect within the available data. Upper limb muscles
346 data only included Biceps Brachii muscle thickness, reaching a moderate effect by 35 days.
347 The breakdown of individual muscle thickness effects per muscle is available in
348 supplementary Table 7 and associated summary plots in Figure 7.

349 ***insert Figure 7 here***

350 3.2.6. Peak power

351 Peak power decreased over time. Large effects became apparent by 56 days for jump power
352 and 62 days for Plantar Flexor and Quadriceps muscles. There was insufficient data to
353 determine a time point for when any moderate effects were reached. The breakdown of
354 individual peak power effects per outcome is available in supplementary Table 8 and
355 associated summary plots in Figure 8.

356 ***insert Figure 8 here***

357 3.2.7. Muscle activity

358 Muscle activity (via electromyography) generally decreased over time, however a transient
359 increase was seen in Plantar Flexor, Dorsi Flexor and Quadriceps muscles and only at 20
360 days. In Plantar Flexor and Quadriceps muscles, muscle activity decreased again after 20
361 days, there were no data for Dorsi Flexor muscles beyond 20 days to establish a post 20 day
362 trend. Moderate effects were apparent in upper limb muscle groups by 15 days but not until
363 90 days for Dorsi and Plantar Flexor muscles which were the only muscles with data at the 90
364 day point. The breakdown of individual activity effects per muscle is available in
365 supplementary Table 9 and associated summary plots in Figure 9.

366 ***insert Figure 9 here***

367 3.2.8. Maximal voluntary contraction during one repetition maximum

368 Maximal voluntary contraction during one repetition maximum decreased over time except
369 for other upper limb outcomes that remained mostly unchanged as far as data were available
370 up to 45 days. Moderate effects became apparent by seven days and large effects by 35 days.
371 Other lower limb outcomes that included maximal isometric force during supine squat, hip
372 extensor force and legs total work never reached a large effect, but had no data available
373 beyond 35 days. The breakdown of individual MVC during one repetition maximum effects
374 per muscle is available in supplementary Table 10 and associated summary plots in Figure
375 10. The polynomial trend for Hamstring muscles appeared to be unsafe after 20 days.

376 ***insert Figure 10 here***

377 3.2.9. Power

378 Power decreased over time. Moderate effects became apparent by 7 days and large effects by
379 20 days, although these were only seen in the Quadriceps muscle data. Hamstring, Hip
380 Flexor and upper limb muscles that included elbow flexors and extensors reached moderate
381 effects by 20 days. Plantar Flexors never reached a moderate effect but data were only
382 available at 14 days. Other trunk muscles included trunk flexors and extensors tested in
383 combination within functional movements. The breakdown of individual power effects per
384 muscle is available in supplementary Table 11 and associated summary plots in Figure 11.

385 ***insert Figure 11 here***

386 3.2.10. Performance based

387 Performance based outcomes all worsened over time, as although sit to stand, balance and
388 sprint time outcomes all had positive effects, this was considered a worsening effect within
389 these measures. Endurance reached a large effect by 14 days, jumping a moderate effect at
390 42 days and large by 44 days, sit to stand and balance reached large effects by 60 days and
391 sprint time by 62 days. Data for most outcomes were only available for one time point and so
392 trends over time for individual outcomes are not able to be determined. The breakdown of
393 individual performance based effects per outcome is available in supplementary Table 12 and
394 associated summary plots in Figure 12. It should be noted that while these outcomes are
395 grouped as being performance based for this review, they may differ and each individual
396 measure should be considered on its own merit.

397 ***insert Figure 12 here***

398 4. Discussion

399

400 4.1. Summary of main findings

401 The main finding of the review was that muscle cross-sectional area, volume, shape, size,
402 activity, power, performance, torque and force-based outcomes, at either regional or global
403 level, all decline over time, based on the current evidence base. Moderate effects became
404 apparent in the following order: power and MVC during one repetition maximum (7 days),
405 followed by volume, cross sectional area, torques and strengths, contractile work capacity,
406 thickness and endurance (14 days), then muscle activity (15 days). Large effects became
407 apparent in the following order: volume, cross sectional area (28 days) torques and strengths,
408 thickness (35 days) and peak power (56 days). No large effects were found for muscle
409 activity. There were limited data for contractile work capacity and no large effects were
410 apparent. In general, lower limb and trunk muscles appeared to decline more rapidly than
411 upper limb muscles. Locomotion muscles such as Plantar Flexor and Quadriceps muscles
412 also generally appeared to decline more rapidly than other muscles groups and with larger
413 effect sizes.

414 4.2. Findings within context of Human space mission profiles

415 Human spaceflight missions differ in duration, so results have to be placed into the context of
416 mission profiles and operationally important considerations. Operationally, performance-
417 related measures such as power, MVC, torques and strengths are considered most critical. In
418 terms of mission profiles, typical ISS missions involve approximately 180 days in μG
419 (Bryant, Meza et al. 2017). The provision of time for exercise CM is mandated for these
420 missions and developments have led to improved efficacy over the lifetime of ISS (Trappe,
421 Costill et al. 2009, Ploutz-Snyder 2013, Hackney, Scott et al. 2015). Assuming that the rate
422 of change during bed rest is reasonably transferable to that experienced in μG , the results of
423 this systematic review suggest that large effects would be apparent within a 180 day ISS
424 mission if no exercise CM were employed. That ISS astronauts are able to complete missions
425 without problems from muscle deterioration and successfully return to Earth may provide
426 some level of evidence with which to judge current countermeasures as effective. However,

427 the focus of this review is exploration beyond Low Earth Orbit. Lunar and Martian
428 (exploration) mission profiles were defined in the HUMEX study (Horneck, Facius et al.
429 2006) that modelled exploration mission durations including transit times in μG and
430 planetary stay times in low ($<1\text{G}$) gravity (Figure. 13). HUMEX defined three scenarios,
431 including a Lunar mission with a 180 day surface stay (Horneck, Facius et al. 2003) and two
432 Mars missions with either a 30 or 400 day surface stay (Horneck, Facius et al. 2006). In
433 HUMEX, inter planetary transit time in μG was five days for Lunar missions and 203-213
434 days for Mars.

435 ***insert Figure 13 here***

436 4.2.1.1. Mars

437 It is clear from the findings of this review that changes in muscle outcomes, including
438 performance related measures, with large effects would be observed if no CM were
439 performed during a 200+ day transit to Mars. A risk assessment (Gernand 2004) has
440 highlighted that decreased muscle mass, strength and endurance is likely to lead to inability
441 to complete mission critical tasks such as exiting a spacecraft on landing, performing
442 strenuous extra vehicular activity and being functional during increased G_z loading on non-
443 Earth planetary surfaces where a landing support and rehabilitation team may not be
444 available. Therefore, effective CM to prevent muscle deterioration are likely going to be
445 required for Mars missions unless absolute strength mission requirements can be reduced or
446 eliminated, to mitigate risks of crews being unable to perform mission critical tasks and
447 continue to function safely on arrival at Mars. However, based on the occurrence of large
448 effect sizes in the present results only after 28-35 days, exercise CM ‘holidays’ might be
449 considered during Mars transits/orbits to save resources if agencies were confident that
450 moderate changes in muscle performance could be reversed using in-flight exercise
451 equipment and prescriptions.

452 4.2.1.2. Moon

453 The results of this review suggest that exercise CM might not be required during a five day
454 Lunar transit period, as moderate effects on muscle are not likely to be apparent until 7 days.
455 The initial changes in power and MVC might not be functionally limiting enough to risk
456 mission success, compared to muscle size, strength and endurance effects that do not reach a
457 moderate size until 14 days. Therefore, further investigation of any effects within the
458 expected Earth-Lunar transit period, considered against minimal clinically worthwhile and
459 mission critical magnitude changes, may be useful to confirm this finding. As a Lunar
460 landing may occur at 8 days in the HUMEX models, the pre-flight strength of crew and the
461 absolute strength and functional requirements of Lunar landing activities would need to be
462 considered when deciding whether or not employ exercise CM prior to attempting a landing.
463 While not employing exercise CM might be considered for the Earth-Lunar transit period, a
464 recent systematic review of biomechanical responses to reduced gravity (Richter, Braustein et
465 al. 2017) showed that exercise CM would likely be needed during stays on the planetary
466 surfaces of both Moon (0.16g) and Mars (0.38g). As time in both μG and low gravity

467 accumulates over the entire mission duration (196-d in total for the HUMEX model), exercise
468 CM are also likely to be needed during the return to Earth transit. However, not using
469 exercise CM on the return transit might be considered if key muscle outcomes could be
470 maintained at, or restored to, pre-mission levels by the end of a Lunar surface stay. Based on
471 the occurrence of large effect sizes in the present results, in an off-nominal situation, such as
472 an emergency, a longer period, possibly up to around 30 days, without exercise CM might be
473 considered if the risks of moderate-large effects can be managed in some other way, for
474 example, knowing support and a full rehabilitation programme are available at the destination
475 arrival site. As with Mars missions, for long Lunar orbital missions with extended periods in
476 μG , an exercise CM ‘holiday’ of the same duration might be considered if agencies were
477 confident that moderate changes in muscle performance could be reversed in-flight.

478 4.2.2. Individuals more susceptible to μG induced muscle changes

479 An individual with a relatively lower muscle outcome measure may be more susceptible to
480 experiencing a negative functional impact of negative changes in these outcomes compared to
481 someone with greater initial measures. It is expected that most missions will require an
482 absolute (minimal) level of strength to achieve mission critical tasks such as donning/doffing
483 and standing up/moving whilst wearing a space suit in low gravity, hatch opening, and
484 pulling/dragging a fellow crew member wearing a space suit during an emergency. The
485 absolute level is defined as the precise required strength outcome in raw units to achieve a
486 task, as opposed to considering relative changes with effect size or percentage changes. A
487 relative (%) reduction in strength will make all tasks with an absolute strength requirement
488 more challenging for all individuals, but the biggest impact will be felt by those who have a
489 lower initial level of absolute strength. For example, a strong individual might be able to lose
490 30% of their pre-flight strength and still comfortably achieve a mission critical task (and also
491 still be stronger than a weaker individual was prior to flight), whereas a weaker individual
492 might already be close to their physical limit during this task without any deconditioning.
493 Operationally, having an estimate of the most rapid possible rate of change in muscle
494 outcomes may be useful in the case of a crew member with low pre-flight absolute strength,
495 or an individual highly susceptible to μG adaptation. In the present study, the most extreme
496 negative value within the confidence interval for each outcome provides an estimate of the
497 most extreme worst likely true value that might be encountered with exposure to μG . Based
498 on this estimation, the results of this analysis suggest that the change experienced by an
499 individual astronaut might reach a large effect size in some muscles within a seven day lunar
500 transit period for volume, cross sectional area, contractive work capacity, thickness, power
501 and MVC. However, the confidence intervals are wide due to the small sample sizes across
502 the current evidence base, so this estimate should be treated with caution as it may be
503 exaggerated. Individual effects are difficult to determine in a transferable way to the true
504 population from the data currently available or from individual case studies. Ideally, a
505 population selected for their increased susceptible to unloading/ μG -induced muscular
506 adaptation should be studied in a long-duration μG analogue to produce a representable
507 average effect that could be transferred to the true population with more reasonable
508 confidence. Until such data are available, estimating the maximum rate of decline in an

509 individual in response to μG exposure of such a duration will remain difficult. In addition,
510 consideration would also be needed should an individual be selected to perform some tasks in
511 a mission that are not considered mission critical, but are essential to other mission goals. It
512 may be that checking for susceptibility to outcomes that are linked more strongly to mission
513 success is checked and made part of astronaut eligibility screening, it could also be any more
514 susceptible mission critical individuals undergo more rigorous preflight and inflight training
515 protocols or consider use of other more removed countermeasures beyond the scope of this
516 review.

517 Exercise countermeasure development may want to consider focussing on those which might
518 best address the more susceptible outcome changes in this review, volume, cross sectional
519 area, contractive work capacity, thickness, power and MVC while also ensuring any proposed
520 exercises are tailored to tasks considered critical, such as donning/doffing and standing
521 up/moving whilst wearing a space suit in low gravity, hatch opening, and pulling/dragging a
522 fellow crew member wearing a space suit. The impact of any chosen exercise types on future
523 spacecraft exercise hardware would also need further consideration. Future research should
524 consider identifying exercise countermeasures that would best address the more susceptible
525 outcomes and be feasible with any technical constraints of new space vehicles planned for
526 use within Moon and Mars missions.

527 4.2.3. Countermeasure requirement

528 As CM are likely to be needed on the return trip from both Moon and on the journeys to and
529 from Mars, such CM will need developing. Countermeasure devices should support lower
530 limb and trunk muscle exercise as these decline earlier than other body regions and are
531 essential for locomotion and for spinal function on return to G loading (Bamman 1996, Pavy-
532 Le Traon, Heer et al. 2007, Evetts, Caplan et al. 2014, Stokes, Evetts et al. 2016, Winnard,
533 Nasser et al. 2017a). Based on the results of the present study, if exercise CM are used
534 during very short missions/transits (e.g. up to seven days), devices should support exercise
535 that maintains power and maximal force production, as moderate effects appeared early in
536 these performance outcomes. Up to around 15 days, exercise CM might need only to prevent
537 moderate size effects in muscle. Consideration could be made around if lower intensity
538 exercise, or potentially a break in countermeasures would be safe. . However, once μG
539 exposure duration reaches around 30 days and above, large effects in muscle will likely need
540 to be managed and this would likely require devices/prescriptions optimised within the
541 constraints of the vehicle/habitat.

542 This pattern fits current European Space Agency (ESA) ISS Long Duration Mission (LDM)
543 exercise prescriptions (Petersen, Jaekel et al. 2016) that include an initial 20-day
544 familiarisation phase to allow crew to adjust to exercise in μG and minimise injury risk, in
545 which exercise intensity is moderate compared to pre-flight maximum capacity. However, as
546 there is currently no systematic measurement of muscle performance in-flight, the impact of
547 this period of lower intensity exercise on overall changes in muscle during an LDM is
548 unknown. It is also unclear if crew members may have had better results at the end of a
549 mission had they begun exercising more intensely earlier in the mission. Following the 20-

550 day familiarisation period, exercise prescriptions are increased in intensity to 80 %+ maximal
551 capacity. In the final 15-30 days of a long duration mission (greater than 49 days) intensity is
552 kept high, but focus on resistance and running exercises. In flight resistance exercise
553 prescriptions for European astronauts also focus on lower limb muscles (squats, heel raises,
554 deadlifts) ESA has found are most susceptible to μG induced changes from (non systematic)
555 measures that have been taken (Petersen, Jaekel et al. 2016). Similar exercise prescriptions,
556 focussing on lower limb muscles and maintaining outcomes already highlighted in this
557 review, might form a good basis for initial planning for any exercises required for Lunar and
558 Mars missions. Additionally, research on preventing deconditioning of older adults might
559 also be useful as preventing loss of power in functional lower limb muscles is important in
560 this population and simple loading exercises have shown helpful in this context (Byrne,
561 Faure et al. 2016). It should also be noted, however, that a systematic review of in-flight CM
562 for maintaining spinal health in μG found that, while resistance based exercises helped
563 prevent muscle changes, they did not help with non-muscle outcomes such as spinal
564 morphology (Winnard, Nasser et al. 2017a). Moreover, a number of other physiological
565 systems/organs also adapt to μG , including bone and aerobic capacity, but the efficacy of
566 resistance exercise during gravitational unloading on them is unknown as systematic reviews
567 similar to the present study have yet to be performed. Therefore, while the recommendations
568 of this review are expected to help plan CM for *muscle* changes, additional holistic
569 consideration of other physiological systems will likely be required. Finally, any CM
570 development for exploration missions will also have to consider constraints of space vehicles
571 that will be used, such as available physical space, limited number of devices that can be
572 included in the space craft, consumables, generation of heat, carbon dioxide and vibration,
573 which are likely to be more restricted than the ISS (Hackney, Scott et al. 2015). Before any
574 pause in exercise countermeasures could be taken, the results of this review would need to be
575 validated in microgravity and ideally actual astronauts through experimental studies. No
576 such published studies of astronauts not performing exercise to document muscle changes
577 over the time frames considered in this review was found. Space agencies and researchers
578 would also need to consider the ethical implications and acceptability of any such study.

579 4.3. Completeness and quality of current evidence

580 There were missing and limited data across all the outcome measure subgroups, and gaps in
581 the evidence base were clearly shown in the results tables. There was a lack of standardised
582 time points at which measures were recorded, even across studies reporting the same outcome
583 measures. Limited data were found repeatedly for Gluteal and Hip Flexor muscles across
584 several outcome measure subgroups. Data were lacking for contractile work capacity, muscle
585 thickness and peak power outcome measures where further research is recommended to
586 validate the trends seen over time in the current evidence base. No patient reported outcome
587 measures have been reported across the bed rest studies, meaning it is unclear how relevant
588 the measures are to patients (in this case astronauts) (Dawson, Doll et al. 2010, Nelson,
589 Eftimovska et al. 2015). In addition, only seven out of the 75 analysed studies considered
590 functional performance based outcomes that are more likely to be directly relevant to
591 astronauts. While strong efforts on behalf of space agencies to standardise bed rest studies

592 has occurred including listing required surrogate measures(Sunblad, Orlov et al. 2014),
593 patient reported outcomes such as their ability to perform a task felt of value to them, remain
594 missing on the whole. It is recommended that the scientific and space medical operations
595 communities agree on set times points at which outcome measures should be tested to enable
596 easier comparisons across studies and for overall trends to be more easily identifiable. While
597 ESA requires agency bed rest studies to be performed to set standards, it might be beneficial
598 to consider running a specific initiative in the wider Aerospace Medicine field to establish
599 core outcome sets relevant to space medicine operations that should then be used in all
600 associated research. This could be based on recommending use of standard space agency
601 developed tests such as functional and Field Test parameters developed by NASA and Russia
602 The Core Outcome Measures in Effectiveness Trials (COMET) is an example initiative that
603 facilitates development and application of core outcome sets and research has been published
604 on how to reach consensus using such an approach (Prinsen, Vohra et al. 2014). It is also
605 recommended that patient reported outcome measures, and increased reporting of functional
606 performance based outcome measures, be included in both future research and space medical
607 operations to ensure that outcome measures are assessing phenomena that are relevant to
608 astronauts. This recommendation echoes a recent European Space Agency topical team
609 report that also found patient reported outcome measures not being used in space medicine
610 research and operations (Stokes, Evetts et al. 2016). The report recommended the use of such
611 outcomes and suggested potential for development of new such outcome measures
612 specifically for space medicine with operational space medicine input to ensure relevance
613 across research and clinical settings. It would be of further benefit if clinically worthwhile,
614 or concerning, changes were defined for key outcome measures, so that results can be placed
615 into a clinically meaningful context. Reporting results based on clinically meaningful raw
616 changes would likely be more informative to operational decisions compared to the more
617 mechanistic null hypothesis tests, effect size or percentage change measures currently used.
618 The high risk of bias and lack of core outcome measure sets means that the conclusions
619 reached by this review should be treated with some caution. A bed rest study could be
620 performed to confirm the findings of this review. If performed, the study would ideally be a
621 randomised controlled trial comparing inactive bedrest with controls not performing bedrest
622 but controlled for all potential confounding factors. For example, exercise and any other
623 types of muscle interventions would need to be strictly controlled for the period of the study.
624 The bed rest element would ideally comply with all aspects of the AMSRG bed rest quality
625 tool to improve transferability of results to astronauts (Winnard and Nasser 2017). Finally,
626 all modifiable risk of bias elements would need controlling and a risk of bias tool for
627 randomised controlled trials, such as provided by Cochrane (Higgins, Altman et al. 2011),
628 could be used as a guide to check what elements need to be controlled to minimise bias risks.

629 Most of the studies scored four on the bed rest tool, with no studies scoring a full seven
630 points, although thirteen studies scored six. The reasons for marking studies down was
631 mostly due it being unclear if criteria had been met rather than clearly failing a point. The
632 most common unclear criteria was related to restricted sunlight exposure followed by
633 ensuring a fixed daily routine. The high risk of bias results were most commonly caused by
634 not clearly showing how confounding factors were managed and providing adequate

635 description of participation. The participation domain considers participant eligibility
636 criteria, source of participants, baseline descriptions, description of sampling frame and
637 recruitment, description of period and place of recruitment and inclusion/exclusion criteria
638 (Hayden, van der Windt et al. 2013). The sunlight exposure criteria has more impact on bone
639 outcomes (Holick 2004) due to its role in vitamin D levels within human bone homeostasis
640 (Tarver 2013) so might not be a large concern for the muscle outcomes presented in this
641 review. However, it is recommended that future bed rest protocol information be clear on all
642 the criteria assessed on the bed rest quality tool and especially on the fixed daily routine and
643 restricted sunlight points, while also ensuring that information is provided about control of
644 confounding factors to help reduce risk of bias and participation considerations. In addition,
645 studies that assess time sensitive outcomes, such as muscle (in which the results of this
646 review show effects of deconditioning can occur by 7 days), should report any potential for
647 pre-bedrest deconditioning during familiarisation and baseline measure periods and any
648 attempts to control for this. There is potential that participants who are admitted to bed rest
649 facilities several days in advance for control measures could decondition within this period.
650 Some studies state including an ambulatory control period, but none report details of what
651 this involved or if there was potential for pre-bed rest deconditioning to influence results.

652 There was some asymmetry in the funnel plot showing potential publication bias towards
653 studies reporting a decrease in muscle outcomes. However, there were studies present on the
654 increasing side of the plot, so the risk is not likely to be high. In addition, it is expected that
655 many of the muscle outcomes would decrease during a period of inactivity such as bed rest,
656 therefore, it not surprising most studies reported decreases. Therefore, while it appears a risk
657 of reporting bias may exist, the presence of some studies reporting increases and the expected
658 pattern of more decreases being reporting suggest this finding should be treated with caution
659 and the potential risk is likely to be low.

660 4.4. Limitations

661 This review only considered muscle outcomes. Spaceflight is known to affect many more
662 human physiological systems including bone, cardiovascular and vestibular (Pavy-Le Traon,
663 Heer et al. 2007). These results alone, therefore, only provide a muscle based perspective.
664 As typical meta-analysis statistics assume two independent groups (Higgins and Green 2011),
665 a more basic effect size analysis without these assumptions had to be used due to only
666 considering changes over time in the control group of each study. Therefore, some caution
667 should be taken as the mean effect sizes are not weighted and heterogeneity scores are not
668 available. However, as most studies had small sample sizes, a weighted result is not expected
669 to produce largely different results. Additionally, the findings of this review appear to match
670 actual spaceflight findings and patterns, such as the European Space Agency exercise
671 prescription for long duration missions that performs lower intensity exercises for the first 20
672 days. While actual measures are not taken during flight, the 20 days has so far not resulted in
673 any mission critical functional decline (Petersen, Jaekel et al. 2016). The 20 day period
674 would fit with the findings of this review that only moderate effects would be expected
675 before 28 days and gives some partial validation, from actual astronaut data, to the findings
676 of this review. The review is also broad and, in places, the variation around the outcomes

677 appears large suggesting heterogeneity of data may be high, although the large intervals could
678 also be due to the small sample sizes that were a common feature of the included bed rest
679 studies. Due to the broad data set that summarises the entire muscle evidence base, additional
680 data on pre-bedrest fitness of participants was not extracted for analysis. While studies were
681 selected that had healthy adults undergoing spaceflight simulation bedrest, individual
682 physical condition was not considered beyond this. Therefore there may be some limitations
683 to the transferability of astronauts who undergo training with space agencies prior to
684 missions. However, a broad summary of the entire current evidence base with basic effect
685 size analysis was the best way to try to address the overarching research questions, look for
686 high level trends and present a summary of the current state of the complete evidence base.

687 4.5. Conclusions

688 The results of this review suggest that moderate effects on a range of muscle function
689 parameters may occur within 7-14 days of unloading, with large effects within 35 days.
690 Combined with identification of muscle performance requirements for future exploration
691 mission tasks, these data, may support the design of CM programmes to optimise their
692 efficient use without compromising crew safety and mission success. However, the data
693 suggests CM are likely to still be needed for longer transit/orbital periods of 14-28+ days,
694 such as a prolonged Lunar orbit, deep space exploration, or a Mars mission, as moderate
695 effects occur between 7-14 days and large effects by 28 days for most muscle outcomes.
696 However, if large effect sizes occur only after 28-35 days, to save resources, space agencies
697 might consider short missions without exercise CM, or fixed periods of abstinence during
698 longer μG exposures, if they could be confident that moderate changes in muscle
699 performance could be reversed in-flight. Finally, several research gaps are highlighted for
700 future bed rest studies in which standardised time points for measurements should be used
701 and clear information provided on sunlight exposure control, fixed daily routine and control
702 of any confounding factors.

703 Author contributions:

704 Winnard, A.: Initial concept ideas, protocol planning and drafting, search screening,
705 analysing, drafting all manuscript versions, corresponding author
706 Scott, J.: Methods advice, protocol drafting, approving final draft
707 Waters, N.: Data extraction, analysis, drafting final version.
708 Vance, M.¹: Protocol planning, search screening, data analysis, drafting text and checking
709 final version.
710 Caplan, N.: Protocol planning, search screening, methods advice, manuscript drafting and
711 approving final version.

712

713 There are no conflicts of interest or funding sources to declare within the author team beyond
714 author employment as already stated on title page.

715

717 Analysed study list:

- 718 1. (Akima, Kubo et al. 2000)
- 719 2. (Akima, Ushiyama et al. 2003)
- 720 3. (Akima, Katayama et al. 2005)
- 721 4. (Akima, Ushiyama et al. 2007)
- 722 5. (Alkner and Tesch 2004)
- 723 6. (Alkner, Norrbrand et al. 2016)
- 724 7. (Arbeille, Kerbeci et al. 2009)
- 725 8. (Bamman, Hunter et al. 1997)
- 726 9. (Belavy, Richardson et al. 2007)
- 727 10. (Belavy, Hides et al. 2008)
- 728 11. (Belavy, Miokovic et al. 2009)
- 729 12. (Belavy, Miokovic et al. 2009)
- 730 13. (Belavy, Armbrecht et al. 2010)
- 731 14. (Belavy, Armbrecht et al. 2011)
- 732 15. (Belavy, Ohshima et al. 2011)
- 733 16. (Belavy, Bansmann et al. 2011)
- 734 17. (Belavy, Miokovic et al. 2013)
- 735 18. (Belavy, Gast et al. 2017)
- 736 19. (Berg, Larsson et al. 1997)
- 737 20. (Berg, Eiken et al. 2007)
- 738 21. (Berry, Berry et al. 1993)
- 739 22. (Buehring, Belavy et al. 2011)
- 740 23. (Caiozzo, Haddad et al. 2009)
- 741 24. (Cescon and Gazzoni 2010)
- 742 25. (Convertino, Doerr et al. 1989)
- 743 26. (de Boer, Seynnes et al. 2008)
- 744 27. (Dudley, Duvoisin et al. 1989)
- 745 28. (Duvoisin, Convertino et al. 1989)
- 746 29. (Ellis, Kirby et al. 1993)
- 747 30. (English, Ploutz-Snyer et al. 2011)
- 748 31. (English, Mettler et al. 2016)
- 749 32. (Ferrando, Stuart et al. 1995)
- 750 33. (Ferretti, Berg et al. 2001)
- 751 34. (Fu, Wang et al. 2016)
- 752 35. (Funato, Matsuo et al. 1997)
- 753 36. (Gast, John et al. 2012)
- 754 37. (Germain, Guell et al. 1995)
- 755 38. (Greenleaf, Van Beaumont et al. 1983)
- 756 39. (Greenleaf, Bernauer et al. 1989)
- 757 40. (Greenleaf, Lee et al. 1994)
- 758 41. (Holguin, Muir et al. 2007)
- 759 42. (Holt, Macias et al. 2016)

- 760 43. (Kawashima, Akima et al. 2004)
761 44. (Koryak 1995)
762 45. (Koryak 1996)
763 46. (Koryak 1998)
764 47. (Koryak 1998)
765 48. (Koryak 1999)
766 49. (Koryak 2002)
767 50. (Koryak 2010)
768 51. (Koryak 2014)
769 52. (Kouzaki, Masani et al. 2007)
770 53. (Krainski, Hastings et al. 2014)
771 54. (LeBlanc, Gogia et al. 1988)
772 55. (Lee, Schneider et al. 2014)
773 56. (Macias, Cao et al. 2007)
774 57. (Miokovic, Armbrecht et al. 2011)
775 58. (Miokovic, Armbrecht et al. 2012)
776 59. (Miokovic, Armbrecht et al. 2014)
777 60. (Muir, Judex et al. 2011)
778 61. (Mulder, Stegeman et al. 2006)
779 62. (Mulder, Kuebler et al. 2007)
780 63. (Mulder, Gerrits et al. 2008)
781 64. (Mulder, Horstman et al. 2009)
782 65. (Mulder, Gerrits et al. 2009)
783 66. (Narici, Kayser et al. 1997)
784 67. (Pisot, Narici et al. 2008)
785 68. (Portero, Vanhoutte et al. 1996)
786 69. (Reeves, Maganaris et al. 2002)
787 70. (Rittweger, Frost et al. 2005)
788 71. (Rittweger, Moller et al. 2013)
789 72. (Schneider, Lee et al. 2016)
790 73. (Shinohara, Yoshitake et al. 2003)
791 74. (Trappe, Trappe et al. 2001)
792 75. (Trappe, Burd et al. 2007)
- 793 Not analysed study list:
- 794 1. (Belavy, Richardson et al. 2007)
795 2. (Belavy, Ng et al. 2010)
796 3. (Belavy, Wilson et al. 2012)
797 4. (Biolo, Agostini et al. 2008)
798 5. (Cavanagh, Rice et al. 2016)
799 6. (Shenkman, Kozlovskaya et al. 1997)
800 7. (Amorim, Schneider et al. 2006)
801 8. (Rittweger and Felsenberg 2009)

- 802 9. (Koriak Iu 2010)
803 10. (Koriak Iu 2012)
804 11. (Koriak Iu 2013)
805 12. (Koryak 1994)
806 13. (Bamman and Caruso 2000)
807 14. (Bamman 1996)
808 15. (Felsenberg, Belavy et al. 2009)
809 16. (Ferretti 1997)
810 17. (Greenleaf, Bernauer et al. 1994)
811 18. (Grogor'eva and Kozlovskaja 1987)
812 19. (Guo, Guo et al. 2001)
813 20. (Hargens, Watenpaugh et al. 2003)
814 21. (Judith C. Hayes, Roper et al. 1992)
815 22. (Ito, Torikoshi et al. 1994)
816 23. (Jaweed, Grana et al. 1995)
817 24. (Koryak 1995)
818 25. (Kozlovskaja, Grigor'eva et al. 1984)
819 26. (LeBlanc, Schneider et al. 1992)
820 27. (LeBlanc, Rowe et al. 1997)
821 28. (Liu, Huang et al. 2003)
822 29. (Macias, Schneider et al. 2008)
823 30. (Meuche, Schneider et al. 2006)
824 31. (Meuche, Schneider et al. 2005)
825 32. (Milesi, Capelli et al. 1997)
826 33. (Miyoshi, Sato et al. 2001)
827 34. (Moriggi, Vasso et al. 2010)
828 35. (Mulder, Horstman et al. 2011)
829 36. (Netreba, Khusnutdinova et al. 2004)
830 37. (Scott, Martin et al. 2017)

831

832 **References**

- 833 Adams, G. R., V. J. Caiozzo and K. M. Baldwin (2003). "Skeletal muscle unweighting: spaceflight and ground-based models."
834 Journal of Applied Physiology **95**: 2185-2201.
- 835 Akima, H., K. Katayama, K. Sato, K. Ishida, K. Masuda, H. Takada, Y. Watanabe and S. Iwase (2005). "Intensive cycle training
836 with artificial gravity maintains muscle size during bed rest." Aviation Space and Environmental Medicine **76**(10): 923-929.
- 837 Akima, H., K. Kubo, H. Kanehisa, Y. Suzuki, A. Gunji and T. Fukunaga (2000). "Leg-press resistance training during 20 days of
838 6 degrees head-down-tilt bed rest prevents muscle deconditioning." European Journal of Applied Physiology **82**(1): 30-38.
- 839 Akima, H., J. Ushiyama, J. Kubo, S. Tonosaki, M. Itoh, Y. Kawakami, H. Fukuoka, H. Kanehisa and T. Fukunaga (2003).
840 "Resistance training during unweighting maintains muscle size and function in human calf." Medicine and Science in Sports
841 and Exercise **35**(4): 655-662.
- 842 Akima, H., J. I. Ushiyama, J. Kubo, H. Fukuoka, H. Kanehisa and T. Fukunaga (2007). "Effect of unloading on muscle volume
843 with and without resistance training." Acta Astronautica **60**(8): 728-736.
- 844 Alkner, B. A., L. Norrbrand and P. A. Tesch (2016). "Neuromuscular Adaptations Following 90 Days Bed Rest With or
845 Without Resistance Exercise." Aerospace Medicine and Human Performance **87**(7): 610-617.
- 846 Alkner, B. A. and P. A. Tesch (2004). "Knee extensor and plantar flexor muscle size and function following 90 days of bed
847 rest with or without resistance exercise." European Journal of Applied Physiology **93**(3): 294-305.
- 848 Amorim, F. T., S. M. Schneider, S. M. C. Lee, W. L. Boda, D. E. Watenpaugh and A. R. Hargens (2006). "Twins Bed Rest
849 Project: LBNP/Exercise Minimizes Changes in Lean Leg Mass, Strength and Endurance." Medicine and Science in Sports and
850 Exercise **38**(5): S389-S390.
- 851 AMSRG (2018) "Aerospace Medicine Systematic Review Group Data Extraction Form."
- 852 Arbeille, P., P. Kerbeci, A. Capri, C. Dannaud, S. W. Trappe and T. A. Trappe (2009). "Quantification of Muscle Volume by
853 Echography: Comparison with Mri Data on Subjects in Long-Term Bed Rest." Ultrasound in Medicine and Biology **35**(7):
854 1092-1097.
- 855 Baker, E. S., Barratt, M.R., and Wear, M.L. (2008). Human Response to Space Flight. Principles of clinical medicine for space
856 flight. M. R. P. Barratt, S.L. New York, Springer: 27-57.
- 857 Bamman, M. M. (1996). Effects of traditional resistance exercise during bed rest on locomotor muscle, University of
858 Florida.
- 859 Bamman, M. M. and J. F. Caruso (2000). "Resistance exercise countermeasures for space flight: implications of training
860 specificity." J Strength Cond Res **14**(1): 45-49.
- 861 Bamman, M. M., G. R. Hunter, B. R. Stevens, M. E. Guilliams and M. C. Greenisen (1997). "Resistance exercise prevents
862 plantar flexor deconditioning during bed rest." Med Sci Sports Exerc **29**(11): 1462-1468.
- 863 Belavy, D. L., G. Armbrecht, U. Gast, C. Richardson, J. A. Hides and D. Felsenberg (2010). "Countermeasures against lumbar
864 spine deconditioning in prolonged bed rest: resistive exercise with and without whole body vibration." Applied physiology
865 **109**: 1801-1811.
- 866 Belavy, D. L., G. Armbrecht, C. A. Richardson, D. Felsenberg and J. A. Hides (2011). "Muscle atrophy and changes in spinal
867 morphology: is the lumbar spine vulnerable after prolonged bed-rest?" Spine (Phila Pa 1976) **36**(2): 137-145.
- 868 Belavy, D. L., P. M. Bansmann, G. Bohme, P. Frings-Meuthen, M. Heer, J. Rittweger, J. Zange and D. Felsenberg (2011).
869 "Changes in intervertebral disc morphology persist 5 mo after 21-day bed rest." J Appl Physiol (1985) **111**(5): 1304-1314.
- 870 Belavy, D. L., U. Gast and D. Felsenberg (2017). "Exercise and Transversus Abdominis Muscle Atrophy after 60-d Bed Rest."
871 Med Sci Sports Exerc **49**(2): 238-246.
- 872 Belavy, D. L., T. Miokovic, G. Armbrecht and D. Felsenberg (2013). "Hypertrophy in the cervical muscles and thoracic discs
873 in bed rest?" J Appl Physiol (1985) **115**(5): 586-596.
- 874 Belavy, D. L., T. Miokovic, G. Armbrecht, C. A. Richardson, J. Rittweger and D. Felsenberg (2009). "Differential atrophy of
875 the lower-limb musculature during prolonged bed-rest." Eur J Appl Physiol **107**(4): 489-499.
- 876 Belavy, D. L., T. Miokovic, G. Armbrecht, J. Rittweger and D. Felsenberg (2009). "Resistive vibration exercise reduces lower
877 limb muscle atrophy during 56-day bed-rest." J Musculoskelet Neuronal Interact **9**(4): 225-235.
- 878 Belavy, D. L., J. K. Ng, S. J. Wilson, G. Armbrecht, D. F. Stegeman, J. Rittweger, D. Felsenberg and C. A. Richardson (2010).
879 "Influence of prolonged bed-rest on spectral and temporal electromyographic motor control characteristics of the
880 superficial lumbo-pelvic musculature." J Electromyogr Kinesiol **20**(1): 170-179.
- 881 Belavy, D. L., H. Ohshima, M. P. Bareille, J. Rittweger and D. Felsenberg (2011). "Limited effect of fly-wheel and spinal
882 mobilization exercise countermeasures on lumbar spine deconditioning during 90 d bed-rest in the Toulouse LTBR study."
883 Acta Astronautica **69**(7-8): 406-419.
- 884 Belavy, D. L., C. A. Richardson, S. J. Wilson, D. Felsenberg and J. Rittweger (2007). "Tonic-to-phasic shift of lumbo-pelvic
885 muscle activity during 8 weeks of bed rest and 6-months follow up." J Appl Physiol (1985) **103**(1): 48-54.
- 886 Belavy, D. L., C. A. Richardson, S. J. Wilson, J. Rittweger and D. Felsenberg (2007). "Superficial lumbopelvic muscle
887 overactivity and decreased cocontraction after 8 weeks of bed rest." Spine (Phila Pa 1976) **32**(1): E23-29.
- 888 Belavy, D. L., S. J. Wilson, G. Armbrecht, J. Rittweger, D. Felsenberg and C. A. Richardson (2012). "Resistive vibration
889 exercise during bed-rest reduces motor control changes in the lumbo-pelvic musculature." J Electromyogr Kinesiol **22**(1):
890 21-30.
- 891 Belavy, D. L. I., J. A. Hides, S. J. Wilson, W. Stanton, F. C., J. Rittweger, D. Felsenberg and C. A. Richardson (2008). "Resistive
892 Simulated Weightbearing Exercise with Whole Body Vibration Reduces Lumbar Spine Deconditioning in Bed-Rest." Spine
893 **33**(5): 121-131.

894 Berg, H. E., O. Eiken, L. Miklavcic and I. B. Mekjavic (2007). "Hip, thigh and calf muscle atrophy and bone loss after 5-week
895 bedrest inactivity." Eur J Appl Physiol **99**(3): 283-289.

896 Berg, H. E., L. Larsson and P. A. Tesch (1997). "Lower limb skeletal muscle function after 6 wk of bed rest." J Appl Physiol
897 **(1985)** **82**(1): 182-188.

898 Berry, P., I. Berry and C. Manelfe (1993). "Magnetic resonance imaging evaluation of lower limb muscles during bed rest--a
899 microgravity simulation model." Aviat Space Environ Med **64**(3 Pt 1): 212-218.

900 Biolo, G., F. Agostini, B. Simunic, M. Sturma, L. Torelli, J. C. Preiser, G. Deby-Dupont, P. Magni, F. Strollo, P. di Prampero, G.
901 Guarnieri, I. B. Mekjavic, R. Pisot and M. V. Narici (2008). "Positive energy balance is associated with accelerated muscle
902 atrophy and increased erythrocyte glutathione turnover during 5 wk of bed rest." American Journal of Clinical Nutrition
903 **88**(4): 950-958.

904 Brusco, S. (2016). "NASA Built a Mini-Exercise Machine for Long, Cramped Space Missions." Medical Design Technology.
905 Bryant, C., D. Meza, N. Schoenstein and S. Schuh (2017). Understanding the International Space Station Crew Perspective
906 following Long-Duration Missions through Data Analytics & Visualization of Crew Feedback. 8th International Conference
907 on Applied Human Factors and Ergonomics, Los Angeles, CA, NASA Johnson Space Center.

908 Buckey, J. C. (2006). Space Physiology. New York, Oxford University Press.

909 Buehring, B., D. L. Belavy, I. Michaelis, U. Gast, D. Felsenberg and J. Rittweger (2011). "Changes in lower extremity muscle
910 function after 56 days of bed rest." Journal of Applied Physiology **111**(1): 87-94.

911 Byrne, C., C. Faure, D. J. Keene and S. E. Lamb (2016). "Ageing, Muscle Power and Physical Function: A Systematic Review
912 and Implications for Pragmatic Training Interventions." Sports Med **46**(9): 1311-1332.

913 Caiozzo, V. J., F. Haddad, S. Lee, M. Baker, W. Paloski and K. M. Baldwin (2009). "Artificial gravity as a countermeasure to
914 microgravity: a pilot study examining the effects on knee extensor and plantar flexor muscle groups." Journal of Applied
915 Physiology **107**(1): 39-46.

916 Cavanagh, P. R., A. J. Rice, S. C. Novotny, K. O. Genc, R. K. Englehaupt, T. M. Owings, B. Comstock, T. Cardoso, H. Ilaslan, S.
917 M. Smith and A. A. Licata (2016). "Replacement of daily load attenuates but does not prevent changes to the
918 musculoskeletal system during bed rest." Bone Rep **5**: 299-307.

919 Cescon, C. and M. Gazzoni (2010). "Short term bed-rest reduces conduction velocity of individual motor units in leg
920 muscles." Journal of Electromyography and Kinesiology **20**(5): 860-867.

921 Convertino, V. A., D. F. Doerr, K. L. Mathes, S. L. Stein and P. Buchanan (1989). "Changes in Volume, Muscle Compartment,
922 and Compliance of the Lower-Extremities in Man Following 30 Days of Exposure to Simulated Microgravity." Aviation Space
923 and Environmental Medicine **60**(7): 653-658.

924 Dawson, J., H. Doll, R. Fitzpatrick, C. Jenkinson and A. J. Carr (2010). "The routine use of patient reported outcome
925 measures in healthcare settings." British Medical Journal **340**.

926 de Boer, M. D., O. R. Seynnes, P. E. di Prampero, R. Pisot, I. B. Mekjavic, G. Biolo and M. V. Narici (2008). "Effect of 5 weeks
927 horizontal bed rest on human muscle thickness and architecture of weight bearing and non-weight bearing muscles."
928 European Journal of Applied Physiology **104**(2): 401-407.

929 Dudley, G. A., M. R. Duvoisin, V. A. Convertino and P. Buchanan (1989). "Alterations of the in vivo torque-velocity
930 relationship of human skeletal muscle following 30 days exposure to simulated microgravity." Aviat Space Environ Med
931 **60**(7): 659-663.

932 Duvoisin, M. R., V. A. Convertino, P. Buchanan, P. D. Gollnick and G. A. Dudley (1989). "Characteristics and preliminary
933 observations of the influence of electromyostimulation on the size and function of human skeletal muscle during 30 days
934 of simulated microgravity." Aviat Space Environ Med **60**(7): 671-678.

935 Ellis, S., L. C. Kirby and J. E. Greenleaf (1993). "Lower extremity muscle thickness during 30-day 6 degrees head-down bed
936 rest with isotonic and isokinetic exercise training." Aviat Space Environ Med **64**(11): 1011-1015.

937 English, K. L., S. Lee, J. A. Loehr, R. J. Ploutz-Snyder and L. Ploutz-Snyder (2015). "Isokinetic Strength Changes Following
938 Long-Duration Spaceflight on the ISS." Aerospace Medicine and Human Performance **86**(12, Section 2): A68 - A77.

939 English, K. L., J. A. Mettler, J. B. Ellison, M. M. Mamerow, E. Arentson-Lantz, J. M. Pattarini, R. Ploutz-Snyder, M. Sheffield-
940 Moore and D. Paddon-Jones (2016). "Leucine partially protects muscle mass and function during bed rest in middle-aged
941 adults." Am J Clin Nutr **103**(2): 465-473.

942 English, K. L., R. J. Ploutz-Snyder, J. B. Crowell, R. L. Cromwell and L. L. Ploutz-Snyder (2011). "Gender Differences in
943 Isokinetic Strength after 60 and 90 d Bed Rest." Medicine and Science in Sports and Exercise **43**(5): 822-822.

944 Evetts, S., N. Caplan, D. Debuse, G. Lambrecht, V. Damann, N. Petersen and J. Hides (2014). "Post Space Mission Lumbo-
945 Pelvic Neuromuscular Reconditioning: A European Perspective." Aviation, Space and Environmental Medicine **85**(7): 764-
946 765.

947 Felsenberg, D., D. Belavy, T. Miocovic, G. Armbrrecht, G. Beller, U. Gast, H. Roth, H. Schiessl, B. Buehring, F. Dimeo, H.
948 Schubert and J. Rittweger (2009). "Changes of muscle and bone mass and bone marker during simulated weightlessness in
949 exercise and control group- Results from Berlin Bed Rest Study." Bone **44**: S58-S59.

950 Ferrando, A. A., C. A. Stuart, D. G. Brunder and G. R. Hillman (1995). "Magnetic resonance imaging quantitation of changes
951 in muscle volume during 7 days of strict bed rest." Aviat Space Environ Med **66**(10): 976-981.

952 Ferretti, G. (1997). "The effect of prolonged bed rest on maximal instantaneous muscle power and its determinants."
953 International Journal of Sports Medicine **18**: S287-S289.

954 Ferretti, G., H. E. Berg, A. E. Minetti, C. Moia, S. Rampichini and M. V. Narici (2001). "Maximal instantaneous muscular
955 power after prolonged bed rest in humans." J Appl Physiol **(1985)** **90**(2): 431-435.

956 Foing, B. (2016). "Towards A Moon Village: Vision and 964 Opportunities". EGU General Assembly, Vienna Austria, EGU.

957 Fu, A. S., C. H. Wang, H. Z. Qi, F. Li, Z. Wang, F. He, P. Zhou, S. G. Chen and D. Ming (2016). "Electromyography-based
958 analysis of human upper limbs during 45-day head-down bed-rest." Acta Astronautica **120**: 260-269.

959 Funato, K., A. Matsuo, H. Yata, H. Akima, Y. Suzuki, A. Gunji and T. Fukunaga (1997). "Changes in force-velocity and power
960 output of upper and lower extremity musculature in young subjects following 20 days bed rest." J Gravit Physiol **4**(1): S22-
961 30.

962 Gast, U., S. John, M. Runge, R. Rawer, D. Felsenberg and D. L. Belavy (2012). "Short-duration resistive exercise sustains
963 neuromuscular function after bed rest." Med Sci Sports Exerc **44**(9): 1764-1772.

964 Germain, P., A. Guell and J. F. Marini (1995). "Muscle Strength during Bedrest with and without Muscle Exercise as a
965 Countermeasure." European Journal of Applied Physiology and Occupational Physiology **71**(4): 342-348.

966 Gernand, J. M. (2004). Risk Assessment and Control Through Countermeasure System Implementation For Long-Term Crew
967 Exposure to Microgravity, Anaheim, CA, IMECE.

968 Greenleaf, J. E., E. M. Bernauer, A. C. Ertl, R. Bulbulian and M. Bond (1994). "Isokinetic strength and endurance during 30-
969 day 6 degrees head-down bed rest with isotonic and isokinetic exercise training." Aviat Space Environ Med **65**(1): 45-50.

970 Greenleaf, J. E., E. M. Bernauer, A. C. Ertl, T. S. Trowbridge and C. E. Wade (1989). "Work capacity during 30 days of bed
971 rest with isotonic and isokinetic exercise training." J Appl Physiol (1985) **67**(5): 1820-1826.

972 Greenleaf, J. E., L. Lee, S. Ellis, R. H. Selzer and D. A. Ortendahl (1994) "Leg muscle volume during 30-day 6-degree head-
973 down bed rest with isotonic and isokinetic exercise training." NASA Technical Reports Server.

974 Greenleaf, J. E., W. Van Beaumont, V. A. Convertino and J. C. Starr (1983). "Handgrip and general muscular strength and
975 endurance during prolonged bedrest with isometric and isotonic leg exercise training." Aviat Space Environ Med **54**(8):
976 696-700.

977 Grogor'eva, L. S. and I. B. Kozlovskaja (1987). "[Effect of weightlessness and hypokinesia on the velocity-strength properties
978 of human muscles]." Kosm Biol Aviakosm Med **21**(1): 27-30.

979 Guo, L. G., Z. F. Guo, J. S. Xie and L. J. Wang (2001). "[Effect of 7 d -6 degrees head-down tilt (HDT) on electromyogram of
980 gastrocnemius and anterior tibialis muscles]." Space Med Med Eng (Beijing) **14**(5): 332-335.

981 Hackney, K. J., J. M. Scott, A. M. Hanson, K. L. English, M. E. Downs and L. L. Ploutz-Snyder (2015). "The Astronaut-Athlete:
982 Optimizing Human Performance in Space." J Strength Cond Res **29**(12): 3531-3545.

983 Hargens, A. R. and L. Vico (2016). "Long-duration bed rest as an analog to microgravity." Journal of Applied Physiology
984 **120**(8): 891-903.

985 Hargens, R., D. Watenpaugh, S. Lee, R. Meyer, B. Macias, K. Tanaka, S. Kimura, G. Steinbach, E. Groppo, N. Khalili, W. Boda,
986 D. O'Leary, H. R. J. Shoemaker, M. Monga, M. Rajasekaran, M. Ziegler, S. Smith and S. Schneider (2003). EXERCISE WITHIN
987 LBNP AS AN ARTIFICIAL GRAVITY COUNTERMEASURE. NASA Technical Reports Server, NASA.

988 Hayden, J. A., D. A. van der Windt, J. L. Cartwright, P. Cote and C. Bombardier (2013). "Assessing bias in studies of
989 prognostic factors." Ann Intern Med **158**(4): 280-286.

990 Higgins, J., D. Altman and J. Sterne (2011). Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green A.
991 (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration.

992 Higgins, J. P. T. and S. Green. (2011). "Cochrane handbook for systematic reviews of interventions version 5.1.0", from
993 www.handbook.cochrane.org.

994 Holguin, N., J. Muir, H. J. Evans, Y. X. Qin, C. Rubin, M. Wagshul and S. Judex (2007). Mechanical vibrations reduce the
995 intervertebral disc swelling and muscle atrophy from bed rest: 25-+.

996 Holick, M. F. (2004). "Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and
997 cardiovascular disease." American Journal of Clinical Nutrition **80**(6): 1678s-1688s.

998 Holt, J. A., B. R. Macias, S. M. Schneider, D. E. Watenpaugh, S. M. Lee, D. G. Chang and A. R. Hargens (2016). "WISE 2005:
999 Aerobic and resistive countermeasures prevent paraspinal muscle deconditioning during 60-day bed rest in women." J Appl
1000 Physiol (1985) **120**(10): 1215-1222.

1001 Hopkins, W. G., S. W. Marshall, A. M. Batterham and J. Hanin (2009). "Progressive statistics for studies in sports medicine
1002 and exercise science." Med Sci Sports Exerc **41**(1): 3-13.

1003 Horneck, G., R. Facius, M. Reichert, P. Rettberg, W. Seboldt, D. Manzey, B. Comet, A. Maillet, H. Preiss, L. Schauer, C. G.
1004 Dussap, L. Poughon, A. Belyavin, G. Reitz, C. Baumstark-Khan and R. Gerzer (2003). "Humex a study on the survivability and
1005 adaptation of humans to long-duration exploratory missions, part I: Lunar missions." Moon: Science, Exploration and
1006 Utilisation **31**(11): 2389-2401.

1007 Horneck, G., R. Facius, M. Reichert, P. Rettberg, W. Seboldt, D. Manzey, B. Comet, A. Maillet, H. Preiss, L. Schauer, C. G.
1008 Dussap, L. Poughon, A. Belyavin, G. Reitz, C. Baumstark-Khan and R. Gerzer (2006). "HUMEX, a study on the survivability
1009 and adaptation of humans to long-duration exploratory missions, part II: Missions to Mars." Advances in Space Research
1010 **38**(4): 752-759.

1011 Horneck, G., R. Facius, M. Reichert, P. Rettberg, W. Seboldt, D. Manzey, B. Comet, A. Maillet, H. Preiss, L. Schauer, C. G.
1012 Dussap, L. Poughon, A. Belyavin, G. Reitz, C. Baumstark-Khan and R. Gerzer (2006). "HUMEX, a study on the survivability
1013 and adaptation of humans to long-duration exploratory missions, part II: Missions to Mars." Mercury, Mars and Saturn
1014 **38**(4): 752-759.

1015 Horneck, G., R. Facius, M. Reichert, P. Rettberg, W. Seboldt, D. Manzey, B. Comet, A. Maillet, H. Preiss, L. Schauer, C. G.
1016 Dussap, L. Poughon, A. Belyavin, G. Reitz, C. Baumstark-Khan and R. Gerzer (2006). "HUMEX Study on the Survivability and
1017 Adaptation of Humans to Long-Duration Interplanetary and Planetary Environments." European Space Agency Report.

1018 Ito, K., S. Torikoshi, K. Yokozawa, J. Nagano and Y. Suzuki (1994). "Gender differences in muscle strength after 20 days bed
1019 rest." J Gravit Physiol **1**(1): P55-56.

1020 Jaweed, M. M., E. A. Grana, T. P. Glennon, T. N. Monga and B. Mirabi (1995). "Neuromuscular adaptations during 30 days
1021 of cast-immobilization and head-down bedrest." J Gravit Physiol **2**(1): P72-73.

1022 Judith C. Hayes, M. J. L. Roper, Augustus D. Mazzocca, John J. McBrine, Linda H. Barrows, Bernard A. Harris and S. F.
1023 Siconolfi (1992) "Eccentric and Concentric Muscle Performance Following 7 Days of Simulated Weightlessness." NASA
1024 Technical Reports Server.

1025 Kawashima, S., H. Akima, S. Y. Kuno, A. Gunji and T. Fukunaga (2004). "Human adductor muscles atrophy after short
1026 duration of unweighting." Eur J Appl Physiol **92**(4-5): 602-605.

1027 Koriak Iu, A. (2010). "[Neuromuscular responses of the triceps surae muscle to prolonged passive stretch of the foot
1028 extensor muscles under conditions of simulated microgravity]." Fiziol Zh **56**(5): 62-76.

1029 Koriak Iu, A. (2012). "[Contraction properties and musculo-tendinous stiffness of the human triceps surae muscle and their
1030 change as a result of a long-term bed-rest]." Fiziol Zh **58**(2): 66-79.

1031 Koriak Iu, A. (2013). "[Influence of physical training under conditions of 120-day simulated microgravity on contractile
1032 properties and musculo-tendinous stiffness of the triceps surae muscle]." Fiziol Zh **59**(2): 71-84.

1033 Koryak, Y. (1995). "Contractile properties of the human triceps surae muscle during simulated weightlessness." Eur J Appl
1034 Physiol Occup Physiol **70**(4): 344-350.

1035 Koryak, Y. (1995). "Mechanical and electrical adaptation of skeletal muscle to gravitational unloading." J Gravit Physiol **2**(1):
1036 P76-79.

1037 Koryak, Y. (1996). "Mechanical and electrical changes in human muscle after dry immersion." Eur J Appl Physiol Occup
1038 Physiol **74**(1-2): 133-140.

1039 Koryak, Y. (1998). "Effect of 120 days of bed-rest with and without countermeasures on the mechanical properties of the
1040 triceps surae muscle in young women." European Journal of Applied Physiology and Occupational Physiology **78**(2): 128-
1041 135.

1042 Koryak, Y. (1999). "The effects of long-term simulated microgravity on neuromuscular performance in men and women." European Journal of Applied Physiology and Occupational Physiology **79**(2): 168-175.

1043 Koryak, Y. (2002). ""DRY" immersion induces neural and contractile adaptations in the human triceps surae muscle." Environ Med **46**(1-2): 17-27.

1044 Koryak, Y. (2010). "Mechanical Responses of the Human Triceps Surae after Passive "Stretching" Training of the
1045 Plantarflexors in Conditions Modulating Weightlessness." Journal of Human Kinetics **24**: 19-34.

1046 Koryak, Y. A. (1994). "Contractile characteristics of the triceps surae muscle in healthy males during 120-days head-down
1047 tilt (HDT) and countermeasures." J Gravit Physiol **1**(1): P141-143.

1048 Koryak, Y. A. (2014). Influence of simulated microgravity on mechanical properties in the human triceps surae muscle in
1049 vivo. I: effect of 120 days of bed-rest without physical training on human muscle musculo-tendinous stiffness and
1050 contractile properties in young women.

1051 Kouzaki, M., K. Masani, H. Akima, H. Shirasawa, H. Fukuoka, H. Kanehisa and T. Fukunaga (2007). "Effects of 20-day bed
1052 rest with and without strength training on postural sway during quiet standing." Acta Physiologica **189**(3): 279-292.

1053 Kozlovskaja, I. B., L. S. Grigor'eva and G. I. Gevlich (1984). "[Comparative analysis of the effect of weightlessness and its
1054 model on the velocity-strength properties and tonus of human skeletal muscles]." Kosm Biol Aviakosm Med **18**(6): 22-26.

1055 Krainski, F., J. L. Hastings, K. Heinicke, N. Romain, E. L. Pacini, P. G. Snell, P. Wyrick, M. D. Palmer, R. G. Haller and B. D.
1056 Levine (2014). "The effect of rowing ergometry and resistive exercise on skeletal muscle structure and function during bed
1057 rest." Journal of Applied Physiology **116**(12): 1569-1581.

1058 LeBlanc, A., P. Gogia, V. Schneider, J. Krebs, E. Schonfeld and H. Evans (1988). "Calf muscle area and strength changes after
1059 five weeks of horizontal bed rest." Am J Sports Med **16**(6): 624-629.

1060 LeBlanc, A., R. Rowe, H. Evans, S. West, L. Shackelford and V. Schneider (1997). "Muscle atrophy during long duration bed
1061 rest." Int J Sports Med **18 Suppl 4**: S283-285.

1062 LeBlanc, A. D., V. S. Schneider, H. J. Evans, C. Pientok, R. Rowe and E. Spector (1992). "Regional changes in muscle mass
1063 following 17 weeks of bed rest." J Appl Physiol (1985) **73**(5): 2172-2178.

1064 Lee, S. M., S. M. Schneider, A. H. Feiveson, B. R. Macias, S. M. Smith, D. E. Watenpugh and A. R. Hargens (2014). "WISE-
1065 2005: Countermeasures to prevent muscle deconditioning during bed rest in women." J Appl Physiol (1985) **116**(6): 654-
1066 667.

1067 Liu, Y. S., W. F. Huang, X. H. Liu, J. Wang, D. M. Zhao and X. Wu (2003). "[Effects of exercise training during 21 d -6 degrees
1068 head down bed rest on dynamic posture equilibrium and motor coordination]." Space Med Med Eng (Beijing) **16**(4): 264-
1069 268.

1070 Loehr, J. A., S. M. Lee, K. L. English, J. Sibonga, S. M. Smith, B. A. Spiering and R. D. Hagan (2011). "Musculoskeletal
1071 adaptations to training with the advanced resistive exercise device." Med Sci Sports Exerc **43**(1): 146-156.

1072 Macias, B. R., P. Cao, D. E. Watenpugh and A. R. Hargens (2007). "LBNP treadmill exercise maintains spine function and
1073 muscle strength in identical twins during 28-day simulated microgravity." J Appl Physiol (1985) **102**(6): 2274-2278.

1074 Macias, B. R., S. Schneider, S. M. C. Lee, P. Guinet, R. Hughson, S. Smith, D. Watenpugh and A. Hargens (2008). "WISE-
1075 2005: Lower Body Negative Pressure Treadmill and Resistive Exercise Countermeasures Maintain Physiologic Function in
1076 Women during 60-days of Simulated Microgravity." Faseb Journal **22**.

1077 Meuche, S., S. M. Schneider, S. M. C. Lee, B. R. Macias, S. M. Smith, D. E. Watenpugh and A. R. Hargens (2005) "WISE
1078 2005: LBNP Exercise and Flywheel Resistive Exercise as an Effective Countermeasure Combination." NASA Technical
1079 Reports Server.

1082 Meuche, S., S. M. Schneider, S. M. C. Lee, B. R. Macias, S. M. Smith, D. E. Watenpaugh and A. R. Hargens (2006) "Supine
1083 Treadmill Exercise in Lower Body Negative Pressure Combined with Resistive Exercise Counteracts Bone Loss, Reduced
1084 Aerobic Upright Exercise Capacity and Reduced Muscle Strength." [NASA Technical Reports Server](#).
1085 Milesi, S., C. Capelli, J. Denoth, T. Hutchinson, P. E. di Prampero and E. Stussi (1997). "Effects of 17 days bed rest on the
1086 maximal isometric torque of the flexors and extensors of the ankle." *J Gravit Physiol* **4**(2): P125-126.
1087 Miokovic, T., G. Armbrecht, D. Felsenberg and D. L. Belavy (2011). "Differential atrophy of the postero-lateral hip
1088 musculature during prolonged bedrest and the influence of exercise countermeasures." *J Appl Physiol* (1985) **110**(4): 926-
1089 934.
1090 Miokovic, T., G. Armbrecht, D. Felsenberg and D. L. Belavy (2012). "Heterogeneous atrophy occurs within individual lower
1091 limb muscles during 60 days of bed rest." *Journal of Applied Physiology* **113**(10): 1545-1559.
1092 Miokovic, T., G. Armbrecht, U. Gast, R. Rawer, H. J. Roth, M. Runge, D. Felsenberg and D. L. Belavy (2014). "Muscle Atrophy,
1093 Pain, and Damage in Bed Rest Reduced by Resistive (Vibration) Exercise." *Medicine and Science in Sports and Exercise*
1094 **46**(8): 1506-1516.
1095 Miyoshi, T., T. Sato, H. Sekiguchi, K. Yamanaka, M. Miyazaki, S. Igawa, T. Komeda, K. Nakazawa and H. Yano (2001). [Effect
1096 of long-term bedrest on lower leg muscle activation patterns during quiet standing](#).
1097 Moher, D., A. Liberati, J. Tetzlaff and D. Altman (2009). "Preferred Reporting Items for Systematic Reviews and Meta-
1098 Analyses: The PRISMA Statement. ." *PLoS Med* **6**(7).
1099 Moore, A. D., M. E. Downs, S. M. C. Lee, A. H. Feiveson, P. Knudsen and L. Ploutz-Snyder (2014). "Peak exercise oxygen
1100 uptake during and following long-duration spaceflight." *Journal of Applied Physiology* **117**: 231-238.
1101 Moriggi, M., M. Vasso, C. Fania, D. Capitanio, G. Bonifacio, M. Salanova, D. Blottner, J. Rittweger, D. Felsenberg, P.
1102 Cerretelli and C. Gelfi (2010). "Long term bed rest with and without vibration exercise countermeasures: Effects on human
1103 muscle protein dysregulation." *Proteomics* **10**(21): 3756-3774.
1104 Muir, J., S. Judex, Y. X. Qin and C. Rubin (2011). "Postural instability caused by extended bed rest is alleviated by brief daily
1105 exposure to low magnitude mechanical signals." *Gait & Posture* **33**(3): 429-435.
1106 Mulder, E. R., K. H. L. Gerrits, B. U. Kleine, J. Rittweger, D. Felsenberg, A. de Haan and D. F. Stegeman (2009). "High-density
1107 surface EMG study on the time course of central nervous and peripheral neuromuscular changes during 8 weeks of bed
1108 rest with or without resistive vibration exercise." *Journal of Electromyography and Kinesiology* **19**(2): 208-218.
1109 Mulder, E. R., K. H. L. Gerrits, J. Rittweger, D. Felsenberg, D. F. Stegeman and A. de Haan (2008). "Characteristics of fast
1110 voluntary and electrically evoked isometric knee extensions during 56 days of bed rest with and without exercise
1111 countermeasure." *European Journal of Applied Physiology* **103**(4): 431-440.
1112 Mulder, E. R., A. M. Horstman, K. Gerrits, M. Massa, B. U. Kleine, A. de Haan, D. L. Belavy, D. Felsenberg, M. Zwarts and D.
1113 F. Stegeman (2011). "Enhanced physiological tremor deteriorates plantar flexor torque steadiness after bed rest." *J
1114 Electromyogr Kinesiol* **21**(2): 384-393.
1115 Mulder, E. R., A. M. Horstman, D. F. Stegeman, A. de Haan, D. L. Belavy, T. Miokovic, G. Armbrecht, D. Felsenberg and K. H.
1116 Gerrits (2009). "Influence of vibration resistance training on knee extensor and plantar flexor size, strength, and contractile
1117 speed characteristics after 60 days of bed rest." *Journal of Applied Physiology* **107**(6): 1789-1798.
1118 Mulder, E. R., W. M. Kuebler, K. H. L. Gerrits, J. Rittweger, D. Felsenberg, D. F. Stegeman and A. de Haan (2007). "Knee
1119 extensor fatigability after bedrest for 8 weeks with and without countermeasure." *Muscle & Nerve* **36**(6): 798-806.
1120 Mulder, E. R., D. F. Stegeman, K. H. L. Gerrits, M. I. Paalman, J. Rittweger, D. Felsenberg and A. De Haan (2006). "Strength,
1121 size and activation of knee extensors followed during 8 weeks of horizontal bed rest and the influence of a
1122 countermeasure." *European Journal of Applied Physiology* **97**(6): 706-715.
1123 Narici, M. V., B. Kayser, P. Barattini and P. Cerretelli (1997). "Changes in electrically evoked skeletal muscle contractions
1124 during 17-day spaceflight and bed rest." *International Journal of Sports Medicine* **18**: S290-S292.
1125 NASA. (2019). "Human Research Roadmap - list of risks." Retrieved 13th June, 2019.
1126 Nelson, E., E. Eftimovska, C. Lind, A. Hager, J. Wasson and S. Lindblad (2015). "Patient reported outcome measures in
1127 practice." *British Medical Journal (BMJ)* **350**: 7818.
1128 Netreba, A. I., D. R. Khusnutdinova, O. L. Vinogradova and I. B. Kozlovskaya (2004). "Effect of dry immersion in combination
1129 with stimulation of foot support zones upon muscle force-velocity characteristics." *J Gravit Physiol* **11**(2): P129-130.
1130 Ouzzani, M., H. Hammady, Z. Fedorowicz and A. Elmagarmid (2016). "Rayyan—a web and mobile app for systematic
1131 reviews." *Systematic Reviews* **5**(1).
1132 Pavy-Le Traon, A., M. Heer, M. V. Narici, J. Rittweger and J. Vernikos (2007). "From space to Earth: advances in human
1133 physiology from 20 years of bed rest studies (1986-2006)." *European Journal of Applied Physiology* **191**: 143-194.
1134 Petersen, N., P. Jaekel, A. Rosenberger, T. Weber, J. Scott, F. Castrucci, G. Lambrecht, L. Ploutz-Snyder, V. Damann, I.
1135 Kozlovskaya and J. Mester (2016). "Exercise in space: the European Space Agency approach to in-flight exercise
1136 countermeasures for long-duration missions on ISS." *Extrem Physiol Med* **5**: 9.
1137 Pisot, R., M. V. Narici, B. Simunic, M. De Boer, O. Seynnes, M. Jurdana, G. Biolo and I. B. Mekjavic (2008). "Whole muscle
1138 contractile parameters and thickness loss during 35-day bed rest." *European Journal of Applied Physiology* **104**(2): 409-414.
1139 Ploutz-Snyder, L. (2013). "An Evidence Based Approach to Exercise Prescriptions on ISS." [Universities Space Research
1140 Association](#).
1141 Ploutz-Snyder, L., J. Ryder, K. English, F. Haddad and K. Baldwin (2015). "NASA evidence report: Risk of Impaired
1142 Performance Due to Reduced Muscle Mass, Strength, and Endurance " [Human Research Program HRP-47072](#).

1143 Portero, P., C. Vanhoutte and F. Goubel (1996). "Surface electromyogram power spectrum changes in human leg muscles
1144 following 4 weeks of simulated microgravity." European Journal of Applied Physiology and Occupational Physiology **73**(3-4):
1145 340-345.

1146 Prinsen, C. A. C., S. Vohra, M. R. Rose and C. B. Terwee (2014). "Core outcome measures in effectiveness trials (COMET)
1147 initiative: an international delphi study to achieve consensus on how to select outcome measurement instruments for
1148 outcomes included in a 'Core Outcome Set'." Quality of Life Research **23**: 100-101.

1149 Reeves, N. J., C. N. Maganaris, G. Ferretti and M. V. Narici (2002). "Influence of simulated microgravity on human skeletal
1150 muscle architecture and function." J Gravit Physiol **9**(1): P153-154.

1151 Richter, C., B. Braustein, A. Winnard, M. Nasser and T. Weber (2017). "Human Biomechanical and Cardiopulmonary
1152 Responses to Partial Gravity - A Systematic Review." Frontiers in Psychology **8**: 583.

1153 Rittweger, J. and D. Felsenberg (2009). "Recovery of muscle atrophy and bone loss from 90 days bed rest: results from a
1154 one-year follow-up." Bone **44**(2): 214-224.

1155 Rittweger, J., H. M. Frost, H. Schiessl, H. Ohshima, B. Alkner, P. Tesch and D. Felsenberg (2005). "Muscle atrophy and bone
1156 loss after 90 days' bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study."
1157 Bone **36**(6): 1019-1029.

1158 Rittweger, J., K. Moller, M. P. Bareille, D. Felsenberg and J. Zange (2013). "Muscle X-ray attenuation is not decreased during
1159 experimental bed rest." Muscle Nerve **47**(5): 722-730.

1160 Schneider, S. M., S. M. C. Lee, A. H. Feiveson, D. E. Watenpaugh, B. R. Macias and A. R. Hargens (2016). "Treadmill exercise
1161 within lower body negative pressure protects leg lean tissue mass and extensor strength and endurance during bed rest."
1162 Physiological Reports **4**(15).

1163 Scott, J. M., D. S. Martin, R. Ploutz-Snyder, T. Matz, T. Caine, M. Downs, K. Hackney, R. Buxton, J. W. Ryder and L. Ploutz-
1164 Snyder (2017). "Panoramic ultrasound: a novel and valid tool for monitoring change in muscle mass." J Cachexia Sarcopenia
1165 Muscle **8**(3): 475-481.

1166 Shenkman, B. S., I. B. Kozlovskaya, T. L. Nemirovskaya and I. A. Tcheglova (1997). "Human muscle atrophy in
1167 supportlessness: effects of short-term exposure to dry immersion." J Gravit Physiol **4**(2): P137-138.

1168 Shinohara, M., Y. Yoshitake, M. Kouzaki, H. Fukuoka and T. Fukunaga (2003). "Strength training counteracts motor
1169 performance losses during bed rest." J Appl Physiol (1985) **95**(4): 1485-1492.

1170 Sibonga, J. D., E. R. Spector, S. L. Johnston and W. J. Tarver (2015). "Evaluating Bone Loss in ISS Astronauts." Aerospace
1171 Medicine and Human Performance **86**(12): A38-A44.

1172 Smith, S., M. Heer, S. LC, S. JD, P.-S. L and Z. SR (2012). "Benefits for bone from resistance exercise and nutrition in long-
1173 duration spaceflight: evidence from biochemistry and densitometry." Journal of Bone and Mineral Research **27**(9): 1896-
1174 1906.

1175 Stokes, M., S. Evetts and J. Hides (2016). "Guest Editorial - Terrestrial neuro-musculoskeletal rehabilitation and astronaut
1176 reconditioning: reciprocal knowledge transfer." Manual Therapy Supplement on "Terrestrial neuro-musculoskeletal
1177 rehabilitation and astronaut reconditioning: reciprocal knowledge transfer" **xx**: xx-xx.

1178 Stokes, M., S. Evetts, J. Rittweger, T. Weber, N. Caplan, L. Danneels, J. Hides, A. Kuipers, G. Lambrecht, N. Peterson, J. Scott,
1179 A. Winnard, J. Zange, D. Barry, D. Beard, J. Bloomberg, D. Blottner, F. Castrucci, J. Cook, R. Cusack, A.-M. Liphardt, C.
1180 McKay, A. Niehoff and G. Ramdharry (2016). "Recommendations for Future Post-mission Neuro-musculoskeletal
1181 Reconditioning Research and Practice Post-mission Exercise (Reconditioning) Topical Team Report." European Space
1182 Agency Report.

1183 Sunblad, P., O. Orlov, O. Angerer, I. Larina and R. Cromwell (2014). "Guidelines For Standardization Of Bed Rest Studies In
1184 The Spaceflight Context." International Academy of Astronautics.

1185 Tarver, W. J. (2013). Clinical Practice Guidelines for Vitamin D. 84th Aerospace Medical Association Annual Scientific
1186 Meeting. Chicago, IL, Aerospace Medical Association.

1187 Trappe, S. W., D. L. Costill, P. Gallagher, A. Creer, J. R. Peters, H. Evans, D. A. Riley and R. H. Fitts (2009). "Exercise in space:
1188 human skeletal muscle after 6 months aboard the International Space Station." Journal of Applied Physiology **106**: 1159-
1189 1168.

1190 Trappe, S. W., T. A. Trappe, G. A. Lee, J. J. Widrick, D. L. Costill and R. H. Fitts (2001). "Comparison of a space shuttle flight
1191 (STS-78) and bed rest on human muscle function." Journal of Applied Physiology **91**(1): 57-64.

1192 Trappe, T. A., N. A. Burd, E. S. Louis, G. A. Lee and S. W. Trappe (2007). "Influence of concurrent exercise or nutrition
1193 countermeasures on thigh and calf muscle size and function during 60 days of bed rest in women." Acta Physiol (Oxf)
1194 **191**(2): 147-159.

1195 Winnard, A. and M. Nasser (2017) "AMSRG Bed Rest Assessment Tool v1.1." Aerospace Medicine Systematic Review Group
1196 DOI: 10.13140/RG.2.2.21758.89925.

1197 Winnard, A. and M. Nasser, Eds. (2017). AMSRG tool for assessing bed rest methods. In: Winnard, Andrew, Nasser, Mona,
1198 Debuse, Dorothee, Stokes, Maria, Evetts, Simon, Wilkinson, Mick, Hides, Julie and Caplan, Nick (2017) Systematic Review of
1199 countermeasures to minimise physiological changes and risk of injury to the lumbopelvic area following long-term
1200 microgravity. Musculoskeletal Science and Practice, **27** (S1). S5-S14. ISSN 2468-7812, Aerospace Medicine Systematic
1201 Review Group.

1202 Winnard, A., M. Nasser, D. Debuse, M. Stokes, S. Evetts, M. Wilkinson, J. Hides and N. Caplan (2017). "Systematic review of
1203 countermeasures to minimise physiological changes and risk of injury to the lumbopelvic area following long-term
1204 microgravity." Musculoskelet Sci Pract **27 Suppl 1**: S5-S14.

1205 Winnard, A., M. Nasser, D. Debuse, M. Stokes, S. Evetts, M. Wilkinson, J. Hides and N. Caplan (2017a). "Systematic Review
1206 of countermeasures to minimise physiological changes and risk of injury to the lumbopelvic area following long-term
1207 microgravity." Musculoskeletal Science and Practice **27**(S1): S5-S14.

1208

1209

1210 **Figures**

1211 Captions:

- 1212 1. **Fig. 1** PRISMA flow diagram of inclusion/exclusion process
- 1213 2. **Fig. 2** Funnel plot of all effects
- 1214 3. **Fig. 3** Effect size plots for muscle volume over time from individual (grey) and
1215 average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed
1216 line) effect magnitudes and average effect trend line overlaid
- 1217 4. **Fig. 4** Effect size plots for muscle cross sectional over time from individual (grey)
1218 and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2
1219 (dashed line) effect magnitudes and average effect trend line overlaid
- 1220 5. **Fig. 5** Effect size plots for torques and strength area over time from individual (grey)
1221 and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2
1222 (dashed line) effect magnitudes and average effect trend line overlaid
- 1223 6. **Fig. 6** Effect size plots for contractile work capacity over time from individual (grey)
1224 and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2
1225 (dashed line) effect magnitudes and average effect trend line overlaid
- 1226 7. **Fig. 7** Effect size plots for muscle thickness over time from individual (grey) and
1227 average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed
1228 line) effect magnitudes and average effect trend line overlaid
- 1229 8. **Fig. 8** Effect size plots for peak power over time from individual (grey) and average
1230 (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line)
1231 effect magnitudes and average effect trend line overlaid
- 1232 9. **Fig. 9** Effect size plots for EMG muscle activity over time from individual (grey) and
1233 average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed
1234 line) effect magnitudes and average effect trend line overlaid
- 1235 10. **Fig. 10** Effect size plots for MVC during one rep max over time from individual
1236 (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and
1237 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
- 1238 11. **Fig. 11** Effect size plots for power over time from individual (grey) and average
1239 (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line)
1240 effect magnitudes and average effect trend line overlaid
- 1241 12. **Fig. 12** Effect size plots for performance based over time from individual (grey) and
1242 average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed
1243 line) effect magnitudes and average effect trend line overlaid
- 1244 13. **Fig. 13** Mission profiles for 180 day surface stay Lunar mission (bottom) and 493 day
1245 surface stay Mars mission (top), adapted from HUMEX (Horneck, Facius et al. 2003,
1246 Horneck, Facius et al. 2006)




Figure 1 PRISMA flow diagram of inclusion/exclusion process




Figure 2 Funnel plot of all effects




Figure 3 Effect size plots for muscle volume over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 4 Effect size plots for muscle cross sectional area over time from individual

(grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 5 Effect size plots for torques and strength area over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 6 Effect size plots for contractile work capacity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 7 Effect size plots for muscle thickness over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 8 Effect size plots for peak power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 9 Effect size plots for EMG muscle activity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 10 Effect size plots for MVC during one rep max over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 11 Effect size plots for power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.




Figure 12 Effect size plots for performance based over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.





Figure 13 Mission profiles for 180 day surface stay Lunar mission (bottom) and 493 day surface stay Mars mission (top), adapted from HUMEX (Horneck, Facius et al. 2003, Horneck, Facius et al. 2006)

Tables

Main tables (to be included as indicated in the main manuscript):

1. Search strategy for database literature search.
2. Characteristics of analysed studies

Supplementary data tables (to be made available online only and not included in the main manuscript)

3. Average effect sizes over time for muscle volumes
4. Average effect sizes over time for muscle cross sectional areas
5. Average effect sizes over time for torques and strength
6. Average effect sizes over time for contractile work capacity
7. Average effect sizes over time for muscle thickness
8. Average effect sizes over time for peak power
9. Average effect sizes over time for EMG muscle activity
10. Average effect sizes over time for MVC during one rep max
11. Average effect sizes over time for power
12. Average effect sizes over time for EMG muscle activity

Table 1 Search strategy for database literature search.

Search number	Term	Keywords in Boolean logic format
1	Microgravity	“astronaut” OR “spaceflight OR “space flight OR “space*” OR “weightless*” OR “microgravity” OR “micro gravity”
2	Bed rest	“bed-rest” OR “bedrest” OR “bed rest” OR “dry immersion”
3	Muscle	“musc*” OR “strength*”
4	Combined	1 AND 2 AND 3

Table 2 Characteristics of analysed studies

Study (analysis cross reference no.)	Design	n	Outcomes	Bed rest quality tool							TOT	QUIPS risk of bias tool							
				Days	1	2	3	4	5	6		7	1	2	3	4	5	6	OVERALL
Akima et al., 2000 ¹	RCT	4	Cross-sectional area, torque, volume.	20	y	?	?	y	y	?	y	4	M	L	n/a	L	H	L	H
Akima et al., 2003 ²	RCT	6	Cross-sectional area, torque.	20	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Akima et al., 2005 ³	RCT	5	Activity (EMG), volume, MVC.	20	y	y	?	y	y	?	y	5	M	L	n/a	L	M	L	H
Akima et al., 2007 ⁴	RCT	6	Muscle Volume.	20	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Alkner and Tesch 2004 ⁵	RCT	9	Volume, MVC, force, power, torque, activity (EMG).	90	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Alkner et al., 2016 ⁶	RCT	9	Activity (EMG), force,	90	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Arbeille et al., 2009 ⁷	RCT	8	Volume	60	y	y	?	y	y	?	y	5	L	L	n/a	L	M	L	H
Bamman et al., 1997 ⁸	RCT	8	MVC, activity (EMG), torque, Power, work.	14	y	y	?	y	y	?	y	5	L	L	n/a	L	M	L	H
Belavy et al., 2007(a) ⁹	RCT	10		56	n	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Belavy et al., 2008 ¹⁰	RCT	10	Cross-sectional area.	56	?	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Belavy et al., 2009(a) ¹¹	RCT	10	Volume.	56	?	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Belavy et al., 2009(b) ¹²	RCT	10	Volume.	56	?	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Belavy et al., 2010(b) ¹³	RCT	9	Cross-sectional area	60	y	y	y	y	y	?	y	6	H	L	n/a	L	H	L	H
Belavy et al., 2011(a) ¹⁴	RCT	9	Cross-sectional area	60	y	y	y	y	y	?	y	6	M	L	n/a	L	M	L	H
Belavy et al., 2011(b) ¹⁵	RCT	9	Volume	90	y	y	?	y	?	?	y	4	L	L	n/a	L	H	L	H
Belavy et al., 2011(c) ¹⁶	CO	7	Cross-sectional area, Muscle Signal Intensity	21	y	?	?	y	?	?	y	3	M	L	n/a	L	H	L	H
Belavy et al., 2013 ¹⁷	RCT	9	Volume	60	y	y	y	y	y	?	y	6	H	L	n/a	L	H	L	H
Belavy et al., 2016 ¹⁸	RCT	8	Muscle Atrophy	56	?	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Berg et al., 1997 ¹⁹	RCT	7	Torque, activity (EMG), angular velocity, fibre types/size, cross-sectional area	42	y	?	?	y	y	?	y	4	M	L	n/a	L	H	L	H
Berg et al., 2007 ²⁰	RCT	5	MVC, Cross-sectional area	35	n	?	?	y	y	?	y	3	H	L	n/a	L	H	L	H
Berry et al., 1993 ²¹	CO	6	Cross-sectional area	30	y	?	?	y	?	?	y	3	H	L	n/a	L	H	L	H
Buehring et al., 2011 ²²	RCT	10	MVC, activity, Jump Power, Jump Height	56	n	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Caiozzo et al., 2009 ²³	RCT	7	Torque, cross-sectional area	21	y	?	?	y	?	?	y	3	H	L	n/a	L	H	L	H
Cescon & Gazzoni 2010 ²⁴	RCT	4	Single and Global motor unit conduction velocity	14	y	y	?	y	y	?	y	5	L	L	n/a	L	M	L	H
Convertino et al., 1989 ²⁵	B&A	8	cross-sectional area	30	y	?	?	?	?	?	y	2	H	L	n/a	L	H	L	H
De Boer et al., 2008 ²⁶	B&A	10	Thickness	35	n	?	?	y	y	?	y	3	M	L	n/a	L	H	L	H

Study (analysis cross reference no.)	Design	n	Outcomes	Bed rest quality tool							TOT	QUIPS risk of bias tool							
				Days	1	2	3	4	5	6		7	1	2	3	4	5	6	OVERALL
Dudley et al., 1989 ²⁷	B&A	7	Torque	30	y	?	?	?	?	?	y	2	H	L	n/a	L	H	L	H
Duvoisin et al., 1989 ²⁸	TS	3	Torque velocity	30	y	?	?	?	?	?	y	2	H	L	n/a	L	H	L	H
Ellis et al., 1993 ²⁹	CS	5	Thickness	30	y	y	y	y	y	?	y	6	M	L	n/a	L	M	L	H
English et al., 2011 ³⁰	B&A	8	Torque	60	n	y	y	y	y	?	y	5	L	L	n/a	L	M	H	H
English et al., 2016 ³¹	RCT	9	Torque and work	14	?	y	?	y	y	?	y	4	L	L	n/a	L	M	L	H
Ferrando et al., 1995 ³²	B&A	6	Volume	7	?	y	?	y	y	?	y	4	H	L	n/a	L	H	L	H
Ferretti et al., 2001 ³³	TS	7	Cross-sectional area, jump power	42	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Fu et al., 2016 ³⁴	TS	8	Activity (EMG), force.	45	y	y	?	y	y	?	y	5	M	L	n/a	L	M	L	H
Funato et al., 1997 ³⁵	TS	10	Strength, velocity.	20	?	?	?	y	?	?	y	2	M	L	n/a	L	H	L	H
Gast et al., 2012 ³⁶	RCT	9	Jump height & power, sit-to-stand tests, sprint time, leg press (1RM)	60	y	y	y	y	y	?	y	6	L	M	n/a	L	M	L	H
Germain et al., 1995 ³⁷	RCT	6	Torque	28	y	?	?	y	y	?	y	4	M	L	n/a	L	H	L	H
Greenleaf et al., 1983 ³⁸	RCO	7	Hand Grip Endurance	14	?	y	?	?	?	?	y	2	H	L	n/a	L	H	L	H
Greenleaf et al., 1989 ³⁹	RCT	5	Work, torque	30	y	y	?	y	y	?	y	5	M	L	n/a	L	M	L	H
Greenleaf et al., 1994(a) ⁴⁰	RCT	5	Volume.	30	y	y	?	y	y	?	?	4	M	L	n/a	M	H	L	H
Holguin et al. 2007 ⁴¹	RCT	11	Volume	90	Y	Y	?	Y	Y	?	Y	5	H	L	n/a	L	M	L	H
Holt et al., 2016 ⁴²	RCT	8	Cross-sectional area.	60	y	y	y	y	y	?	y	6	L	L	n/a	L	L	L	L
Kawashima et al., 2004 ⁴³	B&A	10	Cross-sectional area.	20	n	y	?	y	y	?	y	4	H	L	n/a	L	H	L	H
Koryak 1995(a) ⁴⁴	B&A	6	MVC, force, time to peak tension, total contraction time.	120	y	?	?	y	y	?	y	4	L	L	n/a	L	M	L	H
Koryak 1996 ⁴⁵	B&A	6	MVC, twitch tension, time to peak tension, total contraction time, surface action potentials.	7	n	?	?	y	?	?	y	2	H	L	n/a	L	H	L	H
Koryak 1998(a) ⁴⁶	B&A	6	Maximal twitch response force, strength, MVC, Time-to peak tension, total contraction time.	120	y	?	?	y	?	?	y	3	M	L	n/a	L	H	L	H
Koryak 1998(b) ⁴⁷	RCT	4	MVC, evoked tetanic tension, maximal twitch tension, twitch time-to-peak tension, total contraction time.	120	y	?	?	y	y	?	y	4	M	L	n/a	L	H	L	H
Koryak 1999 ⁴⁸	B&A	10	MVC, tension of maximal twitch, evoked tetanic tension, time to peak tension, total contraction time.	120	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Koryak 2002 ⁴⁹	B&A	6	Tension of maximal twitch, evoked tetanic tension, time to peak tension, total contraction time, surface action potential.	7	n	?	?	y	y	?	y	3	M	L	n/a	L	M	L	H

Study (analysis cross reference no.)	Design	n	Outcomes	Bed rest quality tool							TOT	QUIPS risk of bias tool							
				Days	1	2	3	4	5	6		7	1	2	3	4	5	6	OVERALL
Koryak 2010 ⁵⁰	RCT	6	MVC, twitch tension, time to peak tension, total contraction time.	60	y	y	?	y	y	?	y	5	M	L	n/a	L	M	L	H
Koryak 2014 ⁵¹	RCT	6	Volume, electromyogram.	20	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Kouzaki et al., 2007 ⁵²	RCT	6	Volume, electromyogram.	20	y	?	?	y	y	?	y	4	M	L	n/a	L	M	L	H
Krainski et al., 2014 ⁵³	RCT	9	Volume, torque.	35	y	y	y	y	y	?	y	6	L	L	n/a	L	L	L	L
LeBlanc et al., 1988 ⁵⁴	B&A	9	Cross-sectional area.	35	n	y	?	y	y	?	y	4	H	L	n/a	L	H	L	H
Lee et al., 2014 ⁵⁵	RCT	24	Torque, 1RM, lean mass.	60	y	y	y	y	y	?	y	6	L	L	n/a	L	L	L	L
Macias et al., 2007 ⁵⁶	RCT	15	Strength, torque	28	y	?	?	y	y	?	y	4	M	L	n/a	L	H	L	H
Miokovic et al., 2011 ⁵⁷	RCT	9	Volume.	60	y	y	y	y	y	?	y	6	M	L	n/a	L	M	L	H
Miokovic et al., 2012 ⁵⁸	RCT	9	Volume.	60	y	y	y	y	y	?	y	6	H	L	n/a	L	H	L	H
Miokovic et al., 2014 ⁵⁹	RCT	8	Volume.	60	y	y	y	y	y	?	y	6	H	L	n/a	L	H	L	H
Muir et al., 2011 ⁶⁰	RCT	13	Strength, postural stability.	90	y	?	y	y	y	?	y	5	M	H	n/a	L	M	L	H
Mulder et al., 2006 ⁶¹	RCT	10	Cross-sectional area.	56	n	y	?	y	?	?	y	3	L	L	n/a	L	H	L	H
Mulder et al., 2007 ⁶²	RCT	10	Torque.	56	?	y	?	y	y	?	y	4	L	L	n/a	L	M	L	H
Mulder et al., 2008 ⁶³	RCT	8	Time to peak tension.	56	?	y	?	y	y	?	y	4	L	L	n/a	L	M	L	H
Mulder et al., 2009(a) ⁶⁴	RCT	9	Cross-sectional area, activity (EMG).	60	y	y	y	y	y	?	y	6	H	L	n/a	L	H	L	H
Mulder et al., 2009(b) ⁶⁵	RCT	10	Knee Extensor MVC.	56	N	y	?	y	y	?	y	4	L	L	n/a	L	M	L	H
Narici et al., 1997 ⁶⁶	CS	8	Cross-sectional area, force.	17	y	?	?	?	?	?	y	2	H	L	n/a	M	H	L	H
Pisot et al., 2008 ⁶⁷	B&A	10	Contraction time, muscle maximal displacement	35	n	y	?	y	y	?	y	4	H	L	n/a	L	H	L	H
Portero et al., 1996 ⁶⁸	B&A	12	MVC.	30	y	?	?	y	?	?	y	3	H	L	n/a	L	H	L	H
Reeves et al., 2002 ⁶⁹	RCT	6	Force, resting fascicle length, fascicle length at mvc	90	y	y	?	y	y	?	y	5	M	L	n/a	L	M	L	H
Rittweger et al., 2005 ⁷⁰	RCT	9	Cross-sectional area.	90	y	y	?	y	?	?	y	4	L	L	n/a	L	H	L	H
Rittweger et al., 2013 ⁷¹	RCT	9	Cross-sectional area.	90	y	y	?	y	?	?	y	4	M	L	n/a	L	M	L	H
Schneider et al., 2016 ⁷²	RCT	8	Torque, work, lean mass.	30	y	y	?	y	y	?	y	5	H	L	n/a	L	L	L	H
Shinohara et al., 2003 ⁷³	RCT	6	MVC, activity EMG	20	y	y	?	y	y	?	y	5	H	L	n/a	L	H	L	H
Trappe et al., 2001 ⁷⁴	CS	8	Torque	17	y	y	?	?	?	?	y	3	H	H	n/a	L	H	L	H
Trappe et al., 2007 ⁷⁵	RCT	8	Volume Force	60	y	y	?	y	y	y	y	6	L	L	n/a	L	M	L	H

Bedrest quality scores: 1 6 degrees head down tilt, 2 controlled diet, 3 fixed daily routine, 4 standardised bed rest phases, 5 uninterrupted bed rest, 6 restricted sunlight exposure, 7 same outcome measures for all. Quips risk of bias tool: 1 participation, 2, attrition, 3 prognostic factor measurement, 4 confounding factors, 5 statistical analysis and reporting. RCT: Randomised Controlled Trial. CO: Cross over. B&A: Before and after. TS: Time series. CS: Cross sectional. RCO: Randomised cross over

Supplementary data tables (to be made available online only and not included in the published paper)

3. Average effect sizes over time for muscle volumes
4. Average effect sizes over time for muscle cross sectional areas
5. Average effect sizes over time for torques and strength
6. Average effect sizes over time for contractile work capacity
7. Average effect sizes over time for muscle thickness
8. Average effect sizes over time for peak power
9. Average effect sizes over time for muscle activity
10. Average effect sizes over time for MVC during one rep max
11. Average effect sizes over time for power
12. Average effect sizes over time for performance based

Table 3 Average effect sizes over time for muscle volumes

	Days												
	7	14	20	27	28	29	35	42	55	56	57	89	90
Plantar Flexor Muscles	-0.3 1.1 ³²	-1.0 1.0 ^{11,12}	-0.4 1.3 ^{4,56}	-0.9 1.0 ^{58,59}	-1.8 1.1 ^{11,12}	-1.2 1.0 ^{5,75}	-1.7 1.1 ⁵³	-2.2 1.2 ^{11,12}	-1.3 1.0 ^{58,59}	-3.2 1.4 ^{11,12}	-2.6 1.3 ⁷⁵	-1.6 1.1 ⁵	
Dorsi Flexor Muscles		-0.4 0.9 ^{11, 12}	-0.1 1.2 ^{1,4,52}	-0.4 1.0 ^{58,59}	-0.5 0.9 ^{11, 12}		-0.5 0.9 ⁵³	-0.8 1.0 ^{11, 12}	-0.7 1.0 ^{58,59}	-2.8 1.3 ^{11, 12}			
Quadriceps Muscles		-1.3 1.1 ²	-0.5 1.3 ^{1,3,4}	-0.7 1.5 ^{8,59}	-1.7 1.2 ^{11,12}	-0.8 1.5 ⁷⁵	-0.6 0.9 ⁵³	-2.2 1.3 ²	-1.1 1.1 ^{7,58,59}	-2.8 1.4 ^{11,12}	-1.3 1.1 ⁷⁵	-1.4 1.1 ⁵	
Hamstring Muscles		-1.1 1.1 ^{11,12}	-0.5 1.3 ^{1,3,4}	-0.5 1.5 ^{8,59,57}	-1 1.1 ^{11,12}			-1.8 1.2 ^{11,12}	-1.1 1.5 ^{8,59,57}	-2.2 1.3 ^{11,12}			
Hip Adductor Muscles		-0.6 1.1 ^{11,12}	1.2 1.5 ^{3,4}	-0.2 1.5 ^{8,59}	-0.7 1.1 ^{11,12}			-1.1 1.1 ^{11,12}	-0.4 1.5 ^{8,59}	-1.1 1.1 ^{11,12}			
Gluteal Muscles				-0.6 1.5 ⁷					-0.7 1.5 ⁷				
Hip Flexor Muscles													-0.3 0.9 ¹⁵
Other Lower Limb Muscles	-0.2 1.2 ³²	-0.7 1 ¹²	-0.5 1.3 ^{1,3,4}	-0.8 1.1 ^{58,59,57}	-0.3 1 ¹²			-0.6 1 ¹²	-0.3 0.9 ^{58,59,57}	-0.9 1.1 ¹²			
Erector Spinae Muscles				0.3 0.9 ¹⁷					0.3 0.9 ¹⁷				-0.5 0.9 ¹⁵
Multifidus Muscle													-0.7 1 ¹⁵
Other Trunk Muscles				0.4 0.9 ¹⁷					0.4 0.9 ¹⁷				-0.2 0.9 ^{15,41}

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 4 Average effect sizes over time for muscle cross sectional areas

	Days																				
	2	7	9	10	14	16	20	21	27	28	29	30	35	37	42	47	55	56	60	89	
Plantar Flexor Muscles	-0.1 1.2 ²⁹	-0.1 1.2 ²⁹			-0.1 1.2 ²⁹	-0.3 1.3 ^{1,2}	-0.8 1.1 ²³			-2.2 1.2 ^{70,71}	-0.2 1.2 ²⁹	-0.9 1.0 ^{21,25}	-0.6 1.1 ^{20,54}							-1.8 1.2 ⁶⁴	-4.5 1.8 ^{70,71}
Dorsi Flexor Muscles							-0.2 1.4 ¹					-1.3 0.9 ²¹	-0.3 0.9 ⁵⁴								
Quadriceps Muscles	-0.1 1.2 ²⁹	-0.1 1.2 ²⁹		-0.7 1.0 ⁶¹	-0.1 1.2 ²⁹	-0.4 1.4 ¹	-0.5 1.1 ²³			-1.3 1.0 ⁶¹	-0.1 1.2 ²⁹		-0.7 1.3 ²⁰	-1.1 1.1 ¹⁹	-1.5 1.1 ⁶¹			-1.5 1.0 ⁶⁴	-1.9 1.1 ^{61,64}		
Hamstring Muscles							-0.4 1.4 ¹														
Hip Adductor Muscles				-0.1 0.9 ⁴³			-0.2 0.9 ⁴³														
Gluteal Muscles													-0.2 1.2 ²⁰								
Hip Flexor Muscles								0.2 1.1 ¹⁶	0.0 0.9 ^{13,14}									0.0 0.9 ^{13,14}		-0.2 1.0 ⁴²	
Other Lower Limb Muscles							-0.6 1.4 ¹					-1.2 1.2 ^{25,21}			-1.0 1.1 ³³						
Erector Spinae Muscles								0.6 1.1 ¹⁶	0.8 1.0 ^{13,14}										-1.0 1.0 ^{13,14}	-1.1 0.9 ¹⁰	-1.1 1.0 ⁴²
Multifidus Muscle	-0.4 1.0 ¹⁸			-0.4 1.0 ¹⁸			-0.5 1.1 ¹⁶	-0.5 0.9 ^{13,14}	-0.6 1.0 ¹⁸						-0.3 1.0 ¹⁸			-0.7 1.0 ^{13,14}	-0.7 1.4 ^{18,10}	-1.1 1.1 ⁴²	
Other Trunk Muscle							-0.1 1.0 ¹⁶	-0.3 0.9 ^{13,14}										-0.4 0.9 ^{13,14}		-1.0 1.1 ⁴²	
Upper Limb Muscles										-0.9 1.0 ^{70,71}											-1.4 1.1 ^{70,71}

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 5 Average effect sizes over time for torques and strength

	Days																
	4	7	10	14	17	20	21	24	26	28	30	38	42	55	56	60	90
Plantar Flexor Muscles				-0.3	0.1	-0.4	-0.2			-0.4	-0.7			-1.7		-1.7	-2.0
				1.0 ^{31,8}	1.0 ⁷⁴	1.1 ²	1.1 ²³			1.0 ⁷²	0.8 ⁶⁸			1.1 ⁶⁴		0.7 ⁵⁵	1.1 ^{5,60}
Dorsi Flexor Muscles										-0.3	-0.6					-0.9	-0.3
										1.0 ⁷²	0.8 ⁶⁸					0.6 ⁵⁵	0.8 ⁶⁰
Quadriceps Muscles	-0.2	-0.3	-0.3	-0.8	-0.4	-0.7	-0.3	-0.6		-0.5	-0.6	-0.9	-2.2	-2.0	-1.0	-1.7	-3.2
	0.9 ⁶⁵	0.9 ⁶⁵	0.9 ⁶⁵	1.0 ³¹	0.9 ⁶⁵	1.4 ¹	0.7 ²³	0.9 ⁶⁵		1.1 ^{37,72}	1.1 ²⁷	0.9 ⁶⁵	1.3 ¹⁹	1.1 ⁶⁴	0.9 ^{62,65}	1.12 ^{55,31}	1.4 ^{5,60,6}
Hamstring Muscles	0.0	-0.1	0.0		-0.1			-0.4		-0.4	-0.2	-0.7			-0.8	-1.7	-0.5
	0.9 ⁶¹	0.9 ⁶¹	0.9 ⁶¹		0.9 ⁶¹			0.9 ⁶¹		1.0 ⁷²	1.1 ²⁷	1.0 ⁶¹			1.0 ⁶¹	0.7 ⁵⁵	0.8 ⁶⁰
Hip Extensor Muscles																	
Hip Flexor Muscles																	
Other Trunk																-2.2	-0.5
																1.5 ^{42,30}	0.9 ^{15,60}
Upper Limb Muscles			-0.1						0.1		-0.4	-0.1					
			1.2 ³⁹						1.2 ³⁹		0.7 ⁵⁶	0.9 ⁵³					

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 6 Average effect sizes over time for contractile work capacity

	Days
	14
Plantar Flexors	-0.6 1.0 ⁸
Quadricpes	-0.6 0.9 ³¹

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 7 Average effect sizes over time for muscle thickness

	Days					
	7	14	26	35	42	56
Plantar Flexor Muscles				-1.4		
				1.0 ²⁶		
Dorsi Flexor Muscles				-0.9		
				0.9 ²⁶		
Quadriceps Muscles				-1.8		
				1.0 ²⁶		
Erector Spinae Muscles	-0.5	-0.5	-0.5		-0.5	-0.5
	1.0 ¹⁸	1.0 ¹⁸	1.0 ¹⁸		1.0 ¹⁸	1.0 ¹⁸
Internal Oblique Muscle		-0.9	-0.9		-0.8	-0.8
		1.0 ¹⁸	1.0 ¹⁸		1.0 ¹⁸	1.0 ¹⁸
Transversus Abdominis Muscle		-1.6	-1.4		-1.4	-1.4
		1.1 ¹⁸	1.1 ¹⁸		1.1 ¹⁸	1.1 ¹⁸
Upper Limb Muscles				0.9		
				0.9 ²⁶		

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 8 Average effect sizes over time for peak power

	Days			
	56	60	62	90
Plantar Flexor Muscles			-1.6	-2.1
			1.1 ⁷⁵	1.2 ⁵
Quadriceps Muscles			-1.4	-1.9
			1.1 ⁷⁵	1.1 ⁵
Jump	-1.6	-2.3		
	1.0 ²²	1.2 ⁶		

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 9 Average effect sizes over time for EMG muscle activity

	Days									
	14	15	20	21	30	45	55	56	90	
Plantar Fexor Muscles	0.0 1.0 ⁸		0.4 1.2 ^{52,73}	-0.2 1.0 ⁶⁴			-0.2 1.0 ⁶⁴	0.2 0.9 ²²	-0.9 1.0 ⁵	
Dorsi Flexor Muscles	-0.5 1.2 ^{8,24}		0.5 1.1 ⁵²							
Quadriceps Muscles	-0.5 1.4 ²⁴		0.3 1.2 ^{3,73}	-0.1 0.9 ⁶⁴			-0.1 0.9 ⁶⁴		-0.9 1.0 ⁵	
Erector Spinae Muscles				-0.3 1.1 ¹⁶						
Mutifidus Muscle				-0.2 1.1 ¹⁶						
Hip Flexor Muscles				-0.2 1.1 ¹⁶						
Shoulder Muscles		-0.6 1.0 ³⁴			-0.5 1.0 ³⁴	-0.3 1.0 ³⁴				
Forearm Muscles		-0.7 1.0 ³⁴			-0.8 1.0 ³⁴	-0.6 1.0 ³⁴				

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 10 Average effect sizes over time for MVC during one rep max

	Days																		
	6	7	10	13	14	15	17	20	26	28	30	35	45	56	60	62	90	120	
Plantar Flexor Muscles		-0.7 1.2 ^{45,49}			-1.1 1.1 ⁸		-0.3 1.0 ⁶⁶	-0.4 1.1 ⁷³							-0.8 0.9 ²²	-1.4 1.3 ⁵⁰	-2.1 1.3 ⁷⁵	-1.7 1.1 ^{69,75}	-2.0 1.5 ^{44,46,47,48,51}
Dorsi Flexor Muscles					-0.1 1.0 ⁸										-0.5 0.6 ⁵⁵				
Quadriceps Muscles		-0.5 1.3 ³⁵			-0.7 1.3 ³⁵			-0.8 1.3 ^{3,35,73}		-0.3 1.0 ⁷²			-1.4 1.4 ²⁰		-1.1 0.6 ⁵⁵	-1.5 1.1 ^{75,36}		-2.4 1.2 ⁵	
Hamstring Muscles		-0.4 1.3 ³⁵			-0.8 1.3 ³⁵			-1.1 1.3 ³⁵		-0.6 1.0 ⁷²									
Hip Flexor Muscle		-0.9 1.3 ³⁵			-1.0 1.3 ³⁵			-1.0 1.3 ³⁵											
Other lower limb	-0.3 1.2 ³⁹			-0.6 1.3 ³⁹				-0.6 1.3 ³⁹		-0.5 1.3 ³⁹			-0.9 1.3 ²⁰						-1.5 1.0 ⁶
Other upper limb		0.0 1.2 ³⁵	0.2 1.2 ³⁹		-0.1 1.2 ³⁵	-0.2 1.0 ³⁴		-0.5 1.3 ³⁵	-0.1 1.2 ³⁹		-0.0 1.0 ³⁴	-0.0 1.2 ²⁰	-0.0 1.0 ³⁴						

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 11 Average effect sizes over time for power

	Days		
	7	14	20
Plantar Fexor Muscles		-0.5	
		1.0 ⁸	
Quadricep Muscles	-0.6	-0.9	-1.7
	1.3 ³⁵	1.3 ³⁵	1.5 ³⁵
Hamstring Muscles	-0.1	-0.4	-0.6
	1.2 ³⁵	1.2 ³⁵	1.3 ³⁵
Hip Flexor Muscles	-0.3	-0.5	-0.6
	1.2 ³⁵	1.3 ³⁵	1.3 ³⁵
Other upper limb	-0.0	-0.2	-0.6
	1.2 ³⁵	1.2 ³⁵	1.3 ³⁵

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table

Table 12 Average effect sizes over time for performance based

	Days							
	14	30	42	44	56	60	62	90
Endurance	-1.1 1.1 ³⁸	-1.2 0.9 ⁶⁸						
Jumping			-0.6 1.1 ¹⁹	-2.0 1.3 ³³	-1.2 1.0 ²²	-2.3 1.3 ³⁶		
Sit to stand						-1.1 1.0 ³⁶		
Balance						1.2 0.8 ⁶⁰		1.1 0.8 ⁶⁰
Sprint time							2.1 1.1 ³⁶	

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table